|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/7/26 ¤U¤È 02:22:07
|
2022.01-¤@´Á¼Æ¾Ú¤§Àu¤Æ²³ø(Y¥h¦~¤E¤ë®³³oª©À³¸Ó·|¦n¤@ÂI):ir.aslanpharma.com/static-files/2a7f1481-a0b3-47d1-87ef-e6ed30321475 2022.01-KOL²³ø:ir.aslanpharma.com/static-files/379e7107-c421-4401-b035-e43c4b682d19 2022.05.12- ir.aslanpharma.com/static-files/20941066-3bc3-418b-a970-9951565de0f2 2022.06²³ø-ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c 2022.09.15²³ø-ir.aslanpharma.com/static-files/1511fefc-ba34-4ee4-aac0-32f8bc4754a8 |
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/7/16 ¤W¤È 08:46:02²Ä 236 ½g¦^À³
|
¥xÁÞ¤j ¤p§Ì«D¬ì¯Z¥Í ,Æ[©À¤]¬OªF±½¦è¾ß ,¦^µª±zªº°ÝÃD ,©Î¦³»~®t¿ù»~ ,Y¦³ ,½Ð®ü²[ ¤]½Ð±M·~¤j¤jÌ«ü¾É«ü¥¿ ¦b¤p§ÌªºÆ[©ÀùØ §Ú̥ѩÒq©wªº £\ , £] , ®ÄªG¶q ...¥hpºâ¼Ë¥»¼Æ ·í¼Ë¥»¼Æ½T©w«á (¦p±zÁ|¨Òªº 120 ), ¹êÅç¥X¨Óªº¼Æ¾ÚY¤]½T©w ( ¦p±zÁ|ªº 10/3 ...µ¥ ) «h¥i¥Hºâ¥XPÈ , POWERÈ , ¦A»Pì¥ý©Ò³]©wªº£\ , £]¬Û¤ñ¸û Y«ezµLªkº¡¨¬,¦bÃĮĤ£Åܪº°²³]¤U , ¥u¦³¼W¥[¼Ë¥»¼Æ , ¤è¯à¹F¨ìì¥ý©Ò³]©w£\ , £]ªºªùÂe (PÈ<0.05 , POWERÈ>80 or 90 % ) ¦Ü©ó±zn¤p§Ì¼ÒÀÀªº¥d¤èÈ ,¥Î§Ú¦Û¤v«Ø¥ßªºEXCEL¸Õºâµ²ªG¦p¤U 10/3 , X^2 = 4.227 10/4 , X^2 = 2.911 11/4 , X^2 = 3.733 11/5 , X^2 = 2.596 12/5 , X^2 = 3.358 Y§Ú̱N ( 11/5 )ªº¼Ë¥»¼Æ¥[¿ , ÃĮĤ£ÅÜ ( ORR¤£ÅÜ ) §Y ¥Î¹êÅç²Õ ¹ï·Ó²Õ¼Ë¥»¼Æ¦U¬° 120 , ORR¤H¼Æ 22/10 ºâ±o X^2 = 5.192 ¹F¨ì P < 0.05 ªºÅãµÛ¥Ø¼Ð ¥xÁÞ¤j¥H¤Î·à¤ÍÌ ¨£¯º¤F ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/16 ¤W¤È 12:07:17²Ä 235 ½g¦^À³
|
²q·Q¤j À³¸Ó¬O¤²Õ¼ÒÀÀ¤~¹ï¡A³o¥u¬O²Îp¾Ç¤W¦³Ãö¥d¤èȪº¼ÒÀÀpºâ¤À¨É¡A¤£¬OÁ{§É¸ÕÅç¹ê»Úªºµ²ªG¡A¶È¨Ñ°Ñ¦Ò¦Ó¤w¡A¥t¥~·Q½Ð°Ýpower80©Î90·|¼vÅT¥d¤èȶܡH¥t¥~²q·Q¤jªº¼ÒÀÀ¼Æ¾Ú¥u¬O²Îp¾Ç¤Wªº±Ð¾Ç¤À¨É¦Ó¤w¡A¤j®a¤]À³¾Ç²ß¼ÒÀÀ¸Õºâ¬Ý¬Ý¡I¦p¦¹¤~·|¤£Â_ºë¶i¦¨ªø¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/15 ¤U¤È 11:39:43²Ä 234 ½g¦^À³
|
²q·Q¤j ¦³½Ð«e½ú¸Õºâ¬Ý¬Ý¤U±¥|²Õ¥d¤èÈ¡A¦³¤F¥d¤èȬdªí´N¯à¬ù²¤±À´úPȬO§_¹F¼Ð¡Adf=1 ¹êÅç²Õ/²Õ¹ï·Ó²Õ¦U60¤H¹F¨ìCR+PR¤H¼Æ ¼ÒÀÀ¦p¤U4²Õ 10/3 ¡B10/4 ¡B 11/4 ¡B 11/5 12/5 ±Àºâ²z½×¦¸¼Æ»P¤W±Æ[¹î¦¸¼Æ¥Hdf=1 pºâ¥X¨Óªº¥d¤èȬù¦h¤Ö¡H ÁÂÁ²q·Q¤j |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/15 ¤U¤È 10:48:42²Ä 233 ½g¦^À³
|
¤Ñ©R¤j ¹ï·Ó²Õ4 56 = 60 , ORR 6.7 ¹êÅç²Õ12 48 = 60 , ORR 20 ²z½×¦¸¼Æ¹êÅç²Õ¹ï·Ó²Õ³£¬O¡]16/120¡^x60=8/52 Æ[¹î¦¸¼Æ¹ï·Ó²Õ¬O4/56 ¹êÅç²Õ 12/48 pºâ¥X¨Óªº¥d¤èÈ¥Hdf=1±¡ªp¤U¬dªípȤw¸g¤p©ó0.05 ¡A¹ï·Ó²ÕCR+PR¦³«Ü°ª«Ü°ªªº¾÷²v¸¨¦b3.4.5¤H¥i¥H¼ÒÀÀ¬Ý¬Ý¡C ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¨Ì¾Ú¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/7/15 ¤U¤È 05:22:51²Ä 232 ½g¦^À³
|
Ãö©ó¬ü°ê120¤HÁx¹DÀù¼Ï¯Ã¸ÕÅç½Ð¤j®aÀ°¦£½T»{¤@¤U¦p¤U : 1.¤j®a´£¨ì120¤Hªº¸ÕÅç½s¸¹À³¬ONCT03129074(²Î¤@ÃÒ¨é±i¬ã¨sû©Ò´£),¦ý¦¹¸ÕÅç¤wºM¦^(³sµ²ºô§}²Ä¤»Ó¸ÕÅç).. 2.¦Ó²Ä¥|Ó³sµ²¤~¬OÁx¹DÀù¼Ï¯Ã¸ÕÅç½s¸¹À³¬ONCT03093870,¦ý¨ä¦¬®×¼Æ¬O490¤H.....¦Ó»P120¤H¬ÛÃöªº¶È¦bPrimary Outcome Measures´£¨ì when 70% of the subjects (84 subjects) have experienced a PFS event in Part 1--¤Ï±À84/0.7=120¤H,¬O§_ªí¥Ü¹êÅç/¹ï·Ó¶È»Ý42/42=¦@84¤H´Nºâ²Å¦X³Ì§C¸Ñª¼¤H¼Æ ??? FDA³sµ²¦p¥k : clinicaltrials.gov/ct2/results?cond=Varlitinib&term=&cntry=&state=&city=&dist= |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/15 ¤W¤È 08:12:16²Ä 231 ½g¦^À³
|
¤Ñ©R¤j «e±¤À¨Éªº³oӼƾڹêÅç²Õ¹ï·Ó²Õ¤ñȬù¨â¿´N¹F¼Ð¤F¡A·Q¤£³q¬°¦ó·à¤l¦b¹êÅç²Õ»P¹ï·Ó²Õ¼ÒÀÀ¤¤ORR¤ñȹF3.3¿ÁÙµLªk¹F¼Ð? ¦³¿ìªk¦A§ä¤@¨Ç¨â²Õ¤H¼Æ¦b110-130¥ª¥k¡A¬Ý¬Ý«ÈÆ[¤ÏÀ³²v¤ñȦh¤Ö·|¹LÃö¡C ÁÂÁ¤ѩR¤j¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/14 ¤U¤È 11:44:07²Ä 230 ½g¦^À³
|
¤Ñ©R¤j 1¦Ñ´¤j¬O¬°¤F·V«°_¨£¥Î³ÌÄY®æ¼Ð·Ç´Ó¤J°Ñ¼Æ¡A°Oºâ¥X¨Óµ¹¤j®a°Ñ¦Ò¥Îªº¡A¥u¬O§ÚÌ ¤£²M·¡¦Ñ´¤jªºpºâ¹Lµ{¡H 2npºâ¥d¤èȨ䣧xÃø¡A¨Ì¾Ú¤½¸Õºâ¥X¹êÅç²Õ»P¹ï·Ó²Õ´Á±æ¦¸¼Æ»PÆ[¹î¦¸¼Æ¥N¤J¤½¸Õ¬Û¥[±o¨ì¥d¤èÈ«á¬dªí«K¥i±o¨ì¬ù²¤PÈ ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/7/13 ¤U¤È 10:46:13²Ä 229 ½g¦^À³
|
Varlitinib¦b¦¹¦¸Áx¹DÀù¼Ï¯Ã¸ÕÅç¬O¦³©t¨àÃĸê®æªº,¥[¤W¦Ñ·àªº¬ãµo¤Î¦æ¾Pµ¦²¤¦¨û̳£¬O°ê»Ú¤jÃļtªº¦Ñ¤â~~YORR¹F¼Ð(¨Ì¤Ñ©R¤j°T®§±À¦ô25~28%*0.7=À³¦³17.5~19.5%),¥Î²{¦³2018-ASCO³W¹ºHER+°Ï¤À«á¼Æ¾Ú¨Ó¨úÃÒ¤]¬O¥i¯à©Ê¯Å°ª~~ ¥H¤W¨Ñ°Ñ¦Ò..... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/13 ¤U¤È 10:10:16²Ä 228 ½g¦^À³
|
¤Ñ©R¤j ¨È·à±d¥þ²y¼Ï¯Ã¸ÕÅç¬O¨S¦³¿zÀËHER®a±Ú¡A ¦ý¬O2018 ASCO ©Ò´£¨ì¨º¨Ç¬ÛÃö©Ê¬ã¨s·|¤£·|¬O¤@ºØµ¦²¤¡A¦pªG¤£¿z¿ï¦³®Ä¸Õ¥Îªº¤H¤f§ó¦h¡A¦pªG¼Æ¾Úµo²{¿z¿ïªº¯S©w±Ú¸s®ÄªG¤~·|¥X¨Ó¡A¨ì®ÉÔ¦AÁY¤p¾A¥Î¤H¤f¡A¥u¬O¥i¥H¥Î¿z¿ïªº¦¸±Ú¸sªº¼Æ¾Ú¥h¥Ó½ÐÃÄÃÒ¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/13 ¤U¤È 08:51:47²Ä 227 ½g¦^À³
|
¤Ñ©R¤j ¤G½uÁx¹DÀù¤ÆÀøÃÄ«ÈÆ[¤ÏÀ³²vORR±q¦Ê¤À¤§2-4 ³£¦³¡A¤]¦³¦Ê¤À¤§5-8¡A§ÚÌÀ³¸Ó±Ä¨ú¤ñ¸ûÄY®æ¼Ð·Ç¨Óµû¦ô¹ï·Ó²ÕªºORR¡A§A»{¬°°²³]¹ï·Ó²ÕORR¬O5¡B6¡B7¡B8 ®É¹êÅç²Õn¹F¼Ð»Ýn¦h¤ÖORR¡H |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/7/13 ¤W¤È 11:01:31²Ä 226 ½g¦^À³
|
¤¤°êÁx¹DÀùªºORR¥Dn¸ÕÅç¬O§_¹F¼Ð?¥ý«e1bªº¸ÕÅç¤w¸g¥P¤H«ü¸ô«ü¥X¹F°ª¼Ðªº¼ç¤O¤F~~¦p¤U³sµ²: mops.twse.com.tw/nas/STR/649720180531M001.pdf P15¤ÎP18 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/12 ¤U¤È 03:55:34²Ä 225 ½g¦^À³
|
¤Ñ©R¤j Ó¤H²L¨£:¤¤°êÁx¹DÀù¼Ï¯Ã¸ÕÅç¨S¦³¹ï·Ó²Õ¬O¸ò¶Ç²Î¤ÆÀøÃħ@¤ñ¸û¡A«ÂI°£¤Fn¯à³q¹L²Îp¦ÒÅç¥~¡AORR¼Æ¾Ú³Ì¦n°ª¤@ÂI¥H«áÃĤ~½æ±o¥X¥h¡C¨Ì¾Ú²Î¤@§ëÅU¤ÀªR¹LÃöORR¬ù»Ý15-20 |
|
|
·|û¡Gyu76021610146652 µoªí®É¶¡:2018/7/12 ¤U¤È 02:38:46²Ä 224 ½g¦^À³
|
¤Ñ©R¤j§A¦n..½Ð°Ý§A¤]»{¬°¤¤¸Î¦æ±¡¤w¹L¡H¯à§_½Í½Í§Aªº·Qªk¡H¨È·à±d·|¬O¤U¤@Ó¤¤¸Î¶Ü¡H¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/5 ¤U¤È 11:50:35²Ä 223 ½g¦^À³
|
ºô¸ô¬d¸ß±oª¾¤@¯ë±`¨£45½Sªº¤}¡A»Ý¥X¤O30¦Ü60¤½¤ç¦Ó®g¥Xªº½b¡A®É³t¥i¹F200¤½¨½¡A§e©ßª«½u¸¦æ¡AY¥ÎºÒÅÖºû½b¨¡A³Ì»·¥i®g¨ì800¤½¤Ø¥~¡C¦nªÑ²¼¦p½bn¸ªº°ª¸ªº»·®gªº·Ç·íµMn°V½m¦³¯Àªº¯«®g¤â¥Î¤O©¹«á©Ô |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/7/4 ¤W¤È 09:13:36²Ä 222 ½g¦^À³
|
ÁÂÁ¤ѩR¤j,¥xÁÞ¤j,¤Î¸¤H¤jªº¤À¨É~~ Ãö©ó¤W¤U´å½Õ±±ªº¥æÁpÃö«Y~P13-¤w¦³©ú½Tªº·t¥ÜASLN0001¦bªvÀøªxHER®a±ÚÀù¯gªº¦a¦ì,¥¼¨ÓYÁx¹DÀù¦A¦¸¦³¤W¤U´åÃöÁp©Ê´¦ÅS,´N¬O¦A¦¸ÃÒ©ú¨ä¼sªxªº¦³®Ä©Ê°Õ~~ mops.twse.com.tw/nas/STR/649720180531M001.pdf |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/7/3 ¤U¤È 09:54:13²Ä 221 ½g¦^À³
|
¤Ñ©R¤j§Aªº¤À¨É«Ü§»Æ[¤S¿W¨ì §A´£¨ì : 亜·à±d ¤G½uÁx¹DÀù2/3´ÁÁ{§É¤¤¡A¼W¥[HER®a±Ú¨ü¾¹ªº±´¯Á©Ê¬ã¨s¡A°µ¬°3´Á«eÁx©Êªº¥Íª««ü¼Ð¿zÀ˨̾ڡC ¦]¦¹2´ÁÁ{§É120¤H(60:60)¡A·|¥X²{ORR/PFS ¦³¥Íª««ü¼Ð°Ï¤À¡A¤ÎµL°Ï¤À¥Íª««ü¼Ðªº¤ÀªR¡C ¤£¿z¿ïHER ®a±Ú¨ü¾¹ Åý¤G½uÁx¹DÀù2/3´ÁÁ{§É¸ÕÅç«O¦³¶i¥i§ð°h¥i¦uªºµ¦²¤ªÅ¶¡ ¤G½uÁx¹DÀù¥Ø«e¨S¦³¦nªºÃĪ« ,¤]¨S¦³¼Ð¹vÃÄ, ¦¨¥\ªº¸Ü³o¬OÓÂÅ®ü¥«³õ ¦Ü©óORR PFS ¤ÀªR¤]«Ü¦³ÅÞ¿è, ÁÂÁ¤ѩR¤j °£¤FÁx¹DÀù GÀù «æ©Ê°©ÀH©Ê¥Õ¦å¯f Her2 ¶§©Ê¨ÅÀù ¥~ , ¨È·à±d±þ¤â¯Å²£«~ ASLAN004 ¤µ¤Ñ´£¥XIND ÁÂÁ¸¤H¤j¤À¨É: ASLAN004 ¬°¥þ¤H·½³æ®è§ÜÅé¡AÂê©w IL-13 ¨üÅé £\1 ¦¸³æ¦ì (IL-13R£\1) ¡A±j®Ä§í¨î interleukin-4 (IL-4) ©M interleukin-13 (IL-13) ªº°T¸¹¶Ç»¼¡CIL-4 »P IL-13 ¬°¤Þµo²§¦ì©Ê¥Ö½§ª¢¹L±Ó¤ÏÀ³ªºÃöÁä¡A¦p¥Ö½§µo¬õ©M·kÄo¡CÂÇ¥ÑÂê©w IL-13R£\1 ¨üÅé¡AASLAN004 ¥i±æ´£¨Ñ¾¯¶q»P¥ÎÃÄÀW²v¬Ò¸û§Cªºµ¹ÃĤ覡¡AÀu©ó²{¦³§@¥Î¾÷¨î¬Û¦Pªº²§ ¦ì©Ê¥Ö½§ª¢Àøªk¡CASLAN004 ¿ï¾Ü©Ê¦a»P¥Ø¼Ð²ÓMµ²¦X¥ç¦³±æ´î»´¬ÛÃö°Æ§@¥Î¡C ¨È·à±d-KY °õ¦æªø³Å«iªí¥Ü¡G¡u§Ú̬۫H ASLAN004 ¦³¼ç¤O¦¨¬°¦P¯Å³Ì¨ÎÀøªk¡A»P²§¦ì©Ê¥Ö½§ª¢²{¦³Àøªk¬Û ¤ñ¡AASLAN004 ¾¯¶q»P¥ÎÃÄÀW²v¬Ò¸û§Cªºµ¹ÃĤ覡¥i¤j´T´î¤Ö¯f±wªºt¾á¡C¡v ²§¦ì©Ê¥Ö½§ª¢¬O³Ì±`¨£ªº¥Ö½§¯e¯f¡A¥þ²y¶W¹L 2 »õ¦W¯f±w²`¨ü¨äÂZ 1 ¡A²§¦ì©Ê¥Ö½§ª¢ªº¯SÂI¬°¥Ö½§¬õ¸~¡B«ùÄò ÄY«·kÄo¡A¥i¯àÄY«¼vÅT¯f±w¥Í¬¡«~½è¡C°ª¹F¤T¤À¤§¤@¦¨¤H¯f±wªº¯f±¡µ{«×¹F¤¤«×¦Ü««× 2 ¡A²{¦³ªvÀø¤è¦¡¤£ ¦h¡A¹ï¤j¦h¼Æ¯f±wªº¯f±¡±±¨î¦³¡C Ãö©óASLAN004 ASLAN004 ¬°¥þ¤H·½³æ®è§ÜÅé¡AÂê©w IL-13 ¨üÅé £\1 ¦¸³æ¦ì (IL-13R£\1)¡A¥i±æ¦¨¬°¦P¯Å³Ì¨Î¤§Àøªk¡CASLAN004 ¥Ø«e¦ì©óÁ{§É«e¬ãµo¶¥¬q¡AÂÇ¥ÑÂê©w IL-13R£\1 ¨üÅé¡AASLAN004 ¥i±j®ÄªýÂ_¹L±Ó¤ÏÀ³µo¥Í¾÷Âत§êºtÃöÁ䨤¦âªº interleukin-4 (IL-4) ©M interleukin-13 (IL-13)¤§°T¸¹¶Ç»¼¡A²§¦ì©Ê¥Ö½§ª¢ªº¹L±Ó¤ÏÀ³¥]§t¥Ö½§µo¬õ»P·kÄo¡A¥H¤Î¦p©I§lµu«P¡B³Ý»ï»P«y¹Âµ¥ ¥H¤WÓ¤H¤À¨É¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/7/3 ¤U¤È 04:08:27²Ä 220 ½g¦^À³
|
¨È·à±d»¼¥æ ASLAN004 º¥ó¤HÅéÁ{§É¸ÕÅç¥Ó½Ð 2018 ¦~ 7 ¤ë 3 ¤é¡A·s¥[©Y¡V¥ß°ò©ó¨È¬w¨Ã¶}µo¨ã¥þ²y¥«³õ·s¿oÀøªk¡B¦ì©óÁ{§É¶¥¬q¤§¥Íª«»sÃĤ½¥q¨È·à±d-KY (6497.TT, NASDAQ: ASLN) ¤µ¤é«Å¥¬¦V·s¥[©Y½Ã¥Í¬ì¾Ç§½ (HSA) ´£¥æ ASLAN004 °w¹ï²§¦ì©Ê¥Ö½§ª¢¤§¤@´ÁÁ{§É¸Õ Åç¥Ó½Ð(CTA)¡CASLAN004 ¸ÕÅ礤ªº³æ¤@¾¯¶q»¼¼W¸ÕÅç±N©Û¶Ò°·±d¨ü¸ÕªÌ¡A¦h«¾¯¶q»¼¼W¸ÕÅç«h±N©Û¦¬²§¦ì©Ê ¥Ö½§ª¢±wªÌ¡C ASLAN004 ¬°¥þ¤H·½³æ®è§ÜÅé¡AÂê©w IL-13 ¨üÅé £\1 ¦¸³æ¦ì (IL-13R£\1) ¡A±j®Ä§í¨î interleukin-4 (IL-4) ©M interleukin-13 (IL-13) ªº°T¸¹¶Ç»¼¡CIL-4 »P IL-13 ¬°¤Þµo²§¦ì©Ê¥Ö½§ª¢¹L±Ó¤ÏÀ³ªºÃöÁä¡A¦p¥Ö½§µo¬õ©M·kÄo¡CÂÇ¥ÑÂê©w IL-13R£\1 ¨üÅé¡AASLAN004 ¥i±æ´£¨Ñ¾¯¶q»P¥ÎÃÄÀW²v¬Ò¸û§Cªºµ¹ÃĤ覡¡AÀu©ó²{¦³§@¥Î¾÷¨î¬Û¦Pªº²§ ¦ì©Ê¥Ö½§ª¢Àøªk¡CASLAN004 ¿ï¾Ü©Ê¦a»P¥Ø¼Ð²ÓMµ²¦X¥ç¦³±æ´î»´¬ÛÃö°Æ§@¥Î¡C ¨È·à±d-KY °õ¦æªø³Å«iªí¥Ü¡G¡u§Ú̬۫H ASLAN004 ¦³¼ç¤O¦¨¬°¦P¯Å³Ì¨ÎÀøªk¡A»P²§¦ì©Ê¥Ö½§ª¢²{¦³Àøªk¬Û ¤ñ¡AASLAN004 ¾¯¶q»P¥ÎÃÄÀW²v¬Ò¸û§Cªºµ¹ÃĤ覡¥i¤j´T´î¤Ö¯f±wªºt¾á¡C¡v ²§¦ì©Ê¥Ö½§ª¢¬O³Ì±`¨£ªº¥Ö½§¯e¯f¡A¥þ²y¶W¹L 2 »õ¦W¯f±w²`¨ü¨äÂZ 1 ¡A²§¦ì©Ê¥Ö½§ª¢ªº¯SÂI¬°¥Ö½§¬õ¸~¡B«ùÄò ÄY«·kÄo¡A¥i¯àÄY«¼vÅT¯f±w¥Í¬¡«~½è¡C°ª¹F¤T¤À¤§¤@¦¨¤H¯f±wªº¯f±¡µ{«×¹F¤¤«×¦Ü««× 2 ¡A²{¦³ªvÀø¤è¦¡¤£ ¦h¡A¹ï¤j¦h¼Æ¯f±wªº¯f±¡±±¨î¦³¡C Ãö©óASLAN004 ASLAN004 ¬°¥þ¤H·½³æ®è§ÜÅé¡AÂê©w IL-13 ¨üÅé £\1 ¦¸³æ¦ì (IL-13R£\1)¡A¥i±æ¦¨¬°¦P¯Å³Ì¨Î¤§Àøªk¡CASLAN004 ¥Ø«e¦ì©óÁ{§É«e¬ãµo¶¥¬q¡AÂÇ¥ÑÂê©w IL-13R£\1 ¨üÅé¡AASLAN004 ¥i±j®ÄªýÂ_¹L±Ó¤ÏÀ³µo¥Í¾÷Âत§êºtÃöÁ䨤¦âªº interleukin-4 (IL-4) ©M interleukin-13 (IL-13)¤§°T¸¹¶Ç»¼¡A²§¦ì©Ê¥Ö½§ª¢ªº¹L±Ó¤ÏÀ³¥]§t¥Ö½§µo¬õ»P·kÄo¡A¥H¤Î¦p©I§lµu«P¡B³Ý»ï»P«y¹Âµ¥®ð³Ý¯gª¬¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2018/6/30 ¤W¤È 09:03:15²Ä 219 ½g¦^À³
|
»PADR»ù®t¤w¹F32% §A¤£¶R¡A§Ún¨Ó¶R¤F¡AÖ¶ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/6/30 ¤W¤È 07:52:30²Ä 218 ½g¦^À³
|
¤Ñ©R¤j ³o¦¸¬On»P¹ï·Ó²Õ¤ñ¸ûORR»PPFS ¹ï·Ó²Õ³æÃÄCap ¥Î¦b¤G½uÁx¹DÀù®ÉORR»PPFS±À¦ô¬ù²¤¬O¦h¤Ö¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/6/29 ¤U¤È 11:44:54²Ä 217 ½g¦^À³
|
¤Ñ©R¤j §A¤ÀªR¬ã§P·à¤l¤G½uÁx¹DÀù¹êÅç²Õ»P¹ï·Ó²ÕªºORR PFS ¡H ÁÂÁ¤À¨É ¥DnÀø®Ä«ü¼Ð ¬OPFS ORR ¹êÅç²Õ¨Ï¥ÎVarlitinib + Cap 60¤H ¹ï·Ó²Õ¨Ï¥ÎCap 60¤H |
|
|
·|û¡G±áÄf10141758 µoªí®É¶¡:2018/6/29 ¤U¤È 05:58:40²Ä 216 ½g¦^À³
|
¤Ñ¤jÃÄ·~½æ¤F2797±i |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/6/29 ¤U¤È 05:20:55²Ä 215 ½g¦^À³
|
ÁÂÁ¤ѩR¤j»P©t¨àÃĤjªº¸ê°T¤À¨É ¹ï¤@Ó¨S¦³ÃĪº¯f¯g¡A¯S§O¬OÁx¹DÀù¡A¬ü°êFDA¹ïPȪºn¨D¤ñ¸û¼eÃP¡A³o¤]´N¬O©t¨àÃĦ¨¥\¾÷²v¤ñ¸û°ªªºì¦]¡C¯E¹©»P·à¤l²{ª÷³¡¦ìÁÙºâ¥R¸Î¡A¨¬¥H¿W¥ß§¹¦¨¤T´ÁÁ{§É¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/6/29 ¤U¤È 05:01:23²Ä 214 ½g¦^À³
|
Áx¹DÀù¥þ²y¥Ø¼Ð¯f±w¥»¨Ó´N¤£¦h,¦Ñ·à±Ä¤£¿z¿ïªºµ¦²¤¤Q¤À¥¿½T,¥[¤W¤]¬O«Ü¦³«H¤ß¤~»²¥H¥þ²y¿é¯ÃÁ{§É¸ÕÅç,¦A¸g½Ñ¦ì¤j¤j¸Ô²Ó¤ÀªR«á,¥iµo²{¯u¥¿»ùȵo»Ã¤§´ÁÀ³¤£»·¤w~~~ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/6/29 ¤U¤È 03:12:17²Ä 213 ½g¦^À³
|
¤Ñ©R¤j §A»¡ªº¨S¿ù70%¥ª¥kªºÁx¹DÀùªí²{¤@өΦhÓHER®a±Ú¨ü¾¹.°ÝÃD¬OASLAN 001¥þ²y¼Ï¯Ã¸ÕÅç¨Ã¨S¦³¿zÀËHER®a±Ú¨ü¾¹¡A¥un¬OÁx¹DÀù¯f±w´N¾A¥Î ¾A¥Î½d³ò¬OARQ EGFR=HER1 ¦bÁx¹DÀùªº5~10¿¤~¹ï¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/6/29 ¤U¤È 01:14:07²Ä 212 ½g¦^À³
|
¤Ñ©R¤j,ASLAN001 ¾A¥Î¤H¤f¤£¬O¦Ê¤À¤§70 1 ASLAN 001 ¾A¥ÎÁx¹DÀù¤H¤f¦û¤ñ100% ¤ñderazantinib ¤j¤¿¾A¥Î¤H¤f¤~¹ïderazantinib 2021 ¦~¤~·|§¹¦¨Á{§É¸ÕÅç ,¦~©³¤½§i¤¤°êÁ{§É¸ÕÅç¼Æ¾Ú 2019¦~¤½§i¥þ²y¼Ï¯Ã¸ÕÅç¼Æ¾Ú, «æ©Ê°©Åè©Ê¥Õ¦å¯f¤G´Á¼Æ¾Ú GÀù¤G´Á¼Æ¾Ú ¤]±N¦b¤U¥b¦~¤½§i ) ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò ,½Ð¤Å·í¨Ì¾Ú¬°§ë¸ê |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/6/29 ¤W¤È 11:58:54²Ä 211 ½g¦^À³
|
·s»D¤À¨É! ¦³·sªº¥Í§ÞªÑ¤WÂd¤F¡A¤£¦P©óéw·à¡A¤µ¤Ñ¤@¤WÂd´Nº¦¤F¤T¦¨¡AÆZÃø±oªº! ¥Í§ÞªÑªñ´Á±È°_±¾µP¼é¡A¶h¹F(6576)¤µ¤é¥´ÀY°}¡A¨CªÑ¥H45.2¤¸¤WÂd¡A¦hÀYÅwªY¹ª»R¡AªÑ»ù¥H60¤¸¶}¥X¡A½L¤¤º¦´TÁöµyµy¦¬ÀÄ¡A¦ýº¦´T¤´¦b3¦¨¥H¤W¡A»e¤ë¦æ±¡±j«l¡C ¶h¹F¬ãµo¶i«×³Ì§Öªº«~¶µFP-001«e¦C¸¢Àù¥ÎÃÄ¡A±N¦b¤U¥b¦~¦V¬ü°êFDA´£¥XÃÄÃҥӽСAªk¤Hªí¥Ü¡A¶h¹F¥Í§Þ±Ä±ÂÅv¤À¼íªº¸gÀç¼Ò¦¡¡A¥i±æ¦b¥Ó½ÐÃÄÃÒ«e«á¦V¥~ñq±ÂÅv¦X¬ù¡A¨ì®É¯}¤d¸U¤¸¬üª÷ªº±ÂÅvª÷¦¬¤J¥i±æ¤J³U¡A¥[¤WÃÄ«~¤j¼tFerring½÷â»sÃÄ©e°U¬ãµo¦¬¤J©Ò±o¡A¶h¹F¥Í§Þ¤µ¦~«×Àç¹Bªí²{¬Ý«N¡C ¶h¹F¥Í§ÞFP-001¦b©e°U»s³y°w¾¯¼tªk°êPierre Fabre§¹¦¨³sÄò§å¶q¥Í²£½T®Ä«á¡A¹wp¤U¥b¦~±N¦V¼Ú¬w¤Î¬ü°ê¥Ó½ÐÃÄÃÒ¡C ¶h¹F¥Í§Þ«e¦C¸¢Àù·s¾¯«¬·sÃÄFP-001 25²@§J(¤»Ó¤ë½wÄÀ¾¯«¬)¦AÀò±o¬üFDA®Öã°õ¦æ²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç¡A¥t¥~ªvÀø®ð³Ý¤ÎºC©Êªý¶ë©ÊªÍ¯f³Ð·sÃÄFP-025¤@´Á¤HÅéÁ{§É¸ÕÅç¼Æ¾Ú¤ÀªRµ²ªGÅã¥Ü¥þ¼Æ°·±d¡A¨ü¸ÕªÌ¹ïFP-025³æ¾¯¶q»P¦h¾¯¶q¬Ò¦³¨}¦nªº¦w¥þ©Ê»P@¨ü©Ê¡C¹Î¶¤¤wºî¦XÁ{§É¹êÅçµ²ªG¡A¥¿¦¡´£¥X¼Ú¬ü¤G´ÁÁ{§É¸ÕÅç¥Ó½Ð¡A«ùÄò±À°ÊFP-025ªvÀø®ð³Ý¯f¯gªº¬ãµo¶iµ{¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/6/29 ¤W¤È 10:36:58²Ä 210 ½g¦^À³
|
·PÁ¤ѩR¤jªº¤À¨É~~Ãö©óVARLITINIB(¦Ñ·à)¤ÎDerazantinib(ARQ-087)¦bÁx¹DÀùÁ{§É¸ÕÅ窺¾÷Âà¤À¨É¦p¤U: 1.VARLITINIB:¤p¤À¤lÃĪ«¦b²ÓM¤º§@¥ÎÄÝ©óEGFR¾÷Âà,¯S¦â¬O¥iª½¶¡±µÃö³¬¥|Ó°T¸¹¶Ç»¼(Singal Transdution)~³o ¤]¬O¦Ñ·à¥i²[»\ªvÀø½d³ò¤j©óARQ-087ªºì¦]¨ä¤@,ù¤óªºLapatinib¤]¬O®t¤£¦hªº¾÷¨î,¦ýVAR¥i¤©¥H Ävª§¥ç¥i¦X§@(¦bªñ´ÁMBCªºÁ{§É¸ÕÅ禳«ü¥X¤è¦V)~~~ A.VARLITINIB¤¶²Ð¦p¥k:pubchem.ncbi.nlm.nih.gov/compound/varlitinib#section=Top B.EGFR¾÷Âश²Ð¦p¥k(ÂI¹Ï):www.selleckchem.com/EGFR(HER).html 2.ARQ-087:¤p¤À¤lÃĪ«¦b²ÓM¤º§@¥ÎÄÝ©óFGFR¾÷Âà,Ãö³¬¤@Ó°T¸¹¶Ç»¼~~ A.(ARQ-087)¤¶²Ð¥k:pubchem.ncbi.nlm.nih.gov/compound/Derazantinib#section=Top B.FGFR¾÷Âश²Ð¦p¥k(ÂI¹Ï):www.selleckchem.com/FGFR.html »²¥H°ê»ÚÁx¹DÀù¯e¯f²Îp¼Æ¾Ú¬Ò«ü¥XVARÃĮĥi¯à²[»\½d¬°¬Ò¤j©óARQ-087~~©Ò¥H¤Ñ©R¤j»¡ªº3.5¿¬Oµ´¹ï¦³¥i¯àªº~~ ¥H¤W¨Ñ°Ñ¦Ò~~~ |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/6/28 ¤W¤È 10:12:24²Ä 209 ½g¦^À³
|
¬Ý¨Ó²{¦b¨È·à±d§¹¥þ¨S¦³¤ä¼µ¡A¨C¤ÑµL¶qªº¤U¶^¡A¤µ¤Ñ¬Ý¨Ó40³£³¡ª¾¹D¦u¤£¦uªº¦í¡A²{¦bÅܦ¨¥xªÑ¶^¡A³s±aÅýADR¤]¤U¶^¡AÁÙ¬OµL¶qªº¤U¶^¡A¬Ý°_¨Ó¯uªº«Ü®£©Æ¡AÀqÀqªÑ»ù§Ö¶^¯}40¤F¡A¤£ª¾Ô£®É¥i¥H¤Ï¼u©O? |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/6/27 ¤U¤È 02:57:54²Ä 208 ½g¦^À³
|
¤j®a¦³ªÅ¦A½Æ²ß¤@¹M§a¡ã¡ã¡ã ¥DÃD¡G¥H¨È¬w§@¬°¸~½FÃĪ«¬ãµo¾ÚÂI¥[³t¥þ²y¶}µo¶iµ{---Ápµ²¦p¤U¡G mops.twse.com.tw/nas/STR/649720180531M001.pdf |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/6/27 ¤W¤È 09:12:09²Ä 207 ½g¦^À³
|
ÁöµM¦Ñ·à¦p¦ó¹ï¥¦¤S·b¤S§t¤]³£¤@ª½µw¤£°_¨Ó~¦ý¥¼¨Ó¦³¾÷·|¤£¥Î·b§t´N·|µw±o¹³Æp¥Û¤@¼Ë:¼ç¦b¤j¾÷·|¦p¤U: 2018-2H:A.Asln001-¤¤°êÁx¹DÀùÁ{§É¼Æ¾Ú¦~©³´¦ÅSY¹F¼Ð¦³¾÷·|©ú¦~¨úÃÒ¡]¥H¢Ý¢à¢à¬°¥D,¹F¼Ð¾÷·|°ª¡^ ¡@¡@¡@¡@ B.Asln001-²Ä¤@½uÁx¹DÀù1/2´ÁÁ{§É´Á¤¤¼Æ¾Ú ¡@¡@¡@¡@ C.Asln001-GÀù2´Áªì¨B¼Æ¾Ú´¦ÅS ¡@¡@¡@¡@ D.Asln003-«æ©Ê°©Åè©Ê¥Õ¦å¯f2´Á´Á¤¤¼Æ¾Ú¡ã¡ã¥ç¦³¥i¯à¦ñÀH±ÂÅv¥X¥h¨ú±oÅv§Qª÷ ¡@¡@¡@¡@ E.Asln004-FDA¼f¬d¢×¢Ü¢Ò¶i¤JÁ{§É¸ÕÅç 2019-Q1 : Asln001-Áx¹DÀù2/3¥þ²y¼Ï¯Ã¸ÕÅç,´£¥æ¼Æ¾Ú·Ç³Æ¨úÃÒ ¥H¤W¨Ñ°Ñ¦Ò,¤Å¥HªÑ²¼§ë¸ê¶i¥X¨Ì¾Ú¡ã¡ã |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/6/25 ¤U¤È 02:31:15²Ä 206 ½g¦^À³
|
§Úı±o¬O¥D¤O¥Î¤ß¨}W»¡! ¨È·à±dÃöºò³¬«e¡AADR´«¦¨¥xªÑ»ù®æ¬O58¡A¨È·à±d¨º®ÉÔ¬O48¥ª¥k¡A¤]¬O®t¤F20%¥H¤W¡A¥XÃö¤§«áADR»ù®æ¤]¶^¤U¨Ó¤F¡A´«ºâ¦¨¥xªÑ»ù®æ¬O52¦h¡A¤µ¤Ñ¨È·à±d¦¬½L»ù¬O42.5¡A®t»ù¤]¤F20%¥ª¥k¡A¥i¯à¥D¤O·Qnºû«ù³o¼Ëªº»ù®t§a! 쥻n¤¬¬Û©Ô©ï¡AÅܦ¨»ù®t¤@ª½³£¦b20%¥H¤W¡A§Ú¬Ý¤]¥u¦³¨È·à±d¿ìªº¨ì§a! |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2018/6/25 ¤U¤È 01:40:28²Ä 205 ½g¦^À³
|
éw·à¥i¥H»¡¬O³ÌÄê¥Í§ÞªÑ ADR¸ò¥xÆWìªÑ»ù®t20´X% §Ú¤]¬O¾K¤F |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/6/22 ¤U¤È 02:04:41²Ä 204 ½g¦^À³
|
«¢«¢~~§ï±o¦n,¥H¦³¨âÓ¥«³õ¤W¥«¥i¤¬¬°©Ô©ïªºª¬ªp¦Ó¨¥,ªº½Tª±±o«Ü®t~~ |
|
|
·|û¡G±áÄf10141758 µoªí®É¶¡:2018/6/22 ¤U¤È 01:46:54²Ä 203 ½g¦^À³
|
§ï¦W¥sKY°×·àéw¦n¤F |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/6/22 ¤W¤È 11:31:37²Ä 202 ½g¦^À³
|
²{¦b¨È·à±d·Pı´N¬O¥xÆW§ë¸ê¤H«H¤ß¤£°÷¡AÁöµM¬Q¤ÑADR¶^¤£¤Ö¦ý¬O´«ºâ¦¨¥xªÑÁÙ¬O¦³50¥H¤W¡A¦ý¬O¥xªÑ¸òADR®t»ù¤@ª½³£¦s¦b¡A¤£ª¾¦ó®É¤~¯à¸É¤W¡A«e°}¤lADR¨göt®É¡A¥xªÑ«o³QÃö¸T³¬¡A³o¼Ë¥xÆW§ë¸ê¤H«ç»ò·|¦³«H¤ß¡A¥xªÑ¨º®ÉÔº¦¥u¬O¤ÏÀ³ADRº¦´T¦Ó¤w¡A«o³Q·í¦¨²§±`ª¬ªp¡A·Pı¬OÂd¶R¤¤¤ßÅý¥xÆW§ë¸ê¤H¨S«H¤ßªº¡A¤£´±¶R¶i¨È·à±d¡C |
|
|
·|û¡Gª£¦Ì¯»10146792 µoªí®É¶¡:2018/6/21 ¤U¤È 02:41:29²Ä 201 ½g¦^À³
|
»¡¯uªº¨C¦¸¬Ý³Í°ò½æ«Ü¥û¡A³£Ä±±o³Q¤½¥q¤jªÑªF·í´£´Ú¾÷¡AÁÙ¦n§Ú¤â¸Ì¥t¤@Àɥͧުѫܪ§®ð¡AÄ~Äò¼µµÛ¡AÀ¸´×¤Uµ¥¤[´N¬O§Aªº |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2018/6/21 ¤U¤È 12:13:50²Ä 200 ½g¦^À³
|
¥XÃö«áÁÙ¬Oéw·à¤@ÀY¡A¯fìæìæ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/6/20 ¤U¤È 11:14:10²Ä 199 ½g¦^À³
|
ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.15625 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/6/20 ¤U¤È 11:04:55²Ä 198 ½g¦^À³
|
ÁÂÁ ©t¨àÃĤj seekingalpha.com/article/4180124-aslan-pharmaceuticals-asln-presents-china-healthcare-corporate-day-slideshow 10¦~¤F Áx¹DÀù¨ÌµM¨S¦³®Ö㪺ÃÄ , ¼Ð¹vÃħó¤£n¹Ú·Q , ASLAN 001 ¼Ð¹v§C°Æ§@¥Î¤fªAÃÄ ¥Rº¡Ävª§¼ç¤O ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.156 |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/6/20 ¤U¤È 01:49:45²Ä 197 ½g¦^À³
|
°£¥ý«e¤T®a¬ü¨t¥~¸ê¾÷ºcªº±j¤O¶R¶iµûµ¥¥~..¦p¤U: ¬ü¨t¥~¸êBTIG µûµ¥¶R¶i : $16/ADR ¬Û·í©ó95¶ô/ªÑ-¦Ñ·à¥xªÑ»ù®æ H.C.W µûµ¥¶R¶i : $12/ADR ¬Û·í©ó72¶ô/ªÑ-¦Ñ·à¥xªÑ»ù®æ Piper µûµ¥¶R¶i : $13/ADR ¬Û·í©ó77¶ô/ªÑ-¦Ñ·à¥xªÑ»ù®æ 2018.06.18¦A¥[¤J¬ü¨tÃÒ¨é¬ã¨s¾÷ºcZacks Investment Research±N¥Ø¼Ð»ùq©ó$12/ADR ¬Û·í©ó72¶ô/ªÑ-¦Ñ·à¥xªÑ»ù®æ... ¥H¤W¨Ñ°Ñ¦Ò¤Å·íªÑ²¼¶i¥X¨Ì¾Ú~~~ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/6/20 ¤U¤È 01:40:08²Ä 196 ½g¦^À³
|
©t¨àÃĤj ¥i§_²³æ«ÂI±Ôz¤@¤U¤º®e ÁÂÁ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/6/20 ¤W¤È 11:45:35²Ä 195 ½g¦^À³
|
¬ü°êZacks Investment Research¹ï©ó¦Ñ·àªº±ÀÂ˦p¤U: macondaily.com/2018/06/18/zacks-aslan-pharmaceuticals-adr-rep-5-asln-given-consensus-recommendation-of-buy-by-analysts-updated-updated.html |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/6/13 ¤U¤È 03:14:35²Ä 194 ½g¦^À³
|
½Ð¤Å¦b¦¹¯d¤U¡y¥ô¦ó§Î¦¡¡zªºÁpµ¸¤è¦¡¡A·q½Ð°t¦X¡AÁÂÁ¡IBY¥²´Iºôª©¥D |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/6/13 ¤U¤È 01:02:27²Ä 193 ½g¦^À³
|
www.fool.com/knowledge-center/what-is-an-overweight-rating-on-a-stock.aspx ¦³¦nªº¼Æ¾ÚÁ٥ξá¤ß¥xªÑ»ù®æ»P¬ü°êADR»ù®æ¶Ü? Á٥ξá¤ß±ÂÅv©Î¨ÖÁʶܡH ÃöÁä¬O¼Æ¾Ú¡A¼Æ¾Ú¬O¦ÛÅܶµ¡A»ù®æ¬O¨ÌÅܶµ |
|
|
·|û¡Gellelin10138869 µoªí®É¶¡:2018/6/13 ¤W¤È 11:42:52²Ä 192 ½g¦^À³
|
½Ð°Ýª©¤W¤j¤j¦³¤H¦Ò¼{ª½±µ¶R¨È·à±dªºADR¶Ü |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2018/6/13 ¤W¤È 11:19:20²Ä 191 ½g¦^À³
|
éw·à¯uªº¦³°÷éw ¬ü·àº¦¤£¸òº¦¡A¬ü·à¶^¤@°_¶^ ¦³°÷¤ß»Ä |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/6/8 ¤W¤È 12:27:56²Ä 190 ½g¦^À³
|
¤Ñ©R¤j ·à¤l¤G½uÁx¹DÀù¥þ²y¼Ï¯Ã¸ÕÅç¡A§Aµû¦ô¹ï·Ó²ÕªºÃÄORR¤j¬ù¦h¤Ö?ÁÂÁ ¹êÅç²Õ varlitinib+ capecitabine 60¤H ¹ï·Ó²Õ capecitabine 60¤H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/6/7 ¤U¤È 01:20:22²Ä 189 ½g¦^À³
|
§K¬Ì²Õ´¤Æ¾Ç¬V¦âªk zh.m.wikipedia.org/zh-tw/§K¬Ì²Õ´¤Æ¾Ç |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/6/7 ¤U¤È 12:59:50²Ä 188 ½g¦^À³
|
¬ü¨t¥~¸êBTIG µûµ¥¶R¶i : $16/ADR ¬Û·í©ó95¶ô/ªÑ-¦Ñ·à¥xªÑ»ù®æ H.C.W µûµ¥¶R¶i : $12/ADR ¬Û·í©ó72¶ô/ªÑ-¦Ñ·à¥xªÑ»ù®æ Piper µûµ¥¶R¶i : $13/ADR ¬Û·í©ó77¶ô/ªÑ-¦Ñ·à¥xªÑ»ù®æ ¦Ñ·à¯uªº®t±o«Ü,¥D¤O¤j¤á©p̯uªº¤£n¶R~~¦hÓ¸ÕÅç¶i¤J¼Ï¯Ã¶¥¬q(ªì¨B¤F¸Ñ,¯f±wÀ³¬O¸gImmunohistochemistry¿z¿ï)¥BADR/¥xÆW»ù®t¹F21%,¯uªº¤£n¶R¶Ü? ¥H¤W¨Ñ°Ñ¦Ò,¤Å·íªÑ²¼¶i¥X°Ñ¦Ò¨Ì¾Ú |
|
|
·|û¡Gª£¦Ì¯»10146792 µoªí®É¶¡:2018/6/7 ¤W¤È 12:18:21²Ä 187 ½g¦^À³
|
ADR¶^´N¸òµÛºÆ¶^¡A¦p¤µ¨gº¦»ù®t¤w¨ì¨â®Úº¦°±ªO¡A«o¤£º¦¡A¥t¤HµL¨¥¡A7¤éªº»´äªk»¡§Æ±æ¯à¦A±a°Ê¦æ±¡¡AªÑ»ù¤«¼Q |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/6/6 ¤U¤È 02:06:10²Ä 186 ½g¦^À³
|
Âd¶R¤¤¤ß¤]¬O«Ü©_©Ç¡A²{¦b¨È·à±dªÑ»ù©¹¤Wº¦¡A¨Ã¤£¬O¦]¬°¤H¬°ª£§@¡A¥u¬O¸òADR³s°Ê¦Ó¤w¡A§A¥H¥L³sÄò´X¤Ñº¦´T¶W¹L30%´Nn§ï¤H¤u¼¼¦X¡A²{¦b³£®t»ù20%¡A¦pªGADRÁÙ¬OÄ~Äò¨«´¡A¥[¤W¥xÆW³oÃäÃöºò³¬ªºÃö«Y¡A§Ú¬Ý®t»ù·|¶V¨Ó¶V¦h¡A²{¦b¦pªG´±¶Rªº¤H¡Aµ¥20¸¹¤§«á¡A»ù®t¬O¤@©w·|¤ÏÀ³ªº¡AÂd¶R¤¤¤ßªº¨t²Î¥u·|§ìº¦¶^´T¡A³£¨S¦Ò¼{ADRªº³s°ÊÃö«Y¶Ü?²{¦b¥u¯àµ¥20¸¹ÁÙµ¹¨È·à±d¤½¹D¤F! |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/6/6 ¤U¤È 01:24:53²Ä 185 ½g¦^À³
|
¹ï¤F,¦Ñ·à·à¯uªº®t±o«Ü,¥D¤O¤j¤á©p̯uªº¤£n¶R...~~¦hÓ¸ÕÅç¶i¤J¼Ï¯Ã¶¥¬q¥BADR/¥xÆW»ù®t¹F21%,¯uªº¤£n¶R !! ¥H¤W¨Ñ°Ñ¦Ò,¤Å·íªÑ²¼¶i¥X°Ñ¦Ò¨Ì¾Ú |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/6/6 ¤U¤È 01:13:32²Ä 184 ½g¦^À³
|
§ó¥¿ ARQL - ArQule, Inc ¤w¸gº¦¨ì5.2¬ü¤¸ ¤~¹ï |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/6/6 ¤W¤È 11:24:34²Ä 183 ½g¦^À³
|
ARQL - ArQule, Inc. ¤w¸gº¦¨ì5.5¬ü¤¸¡A·à¤l¬ü°êADR¦¬9.9¬ü¤¸¡A³Ì°ª´¿¬ð¯}10.4¬ü¤¸¡A¥Ø«e¨S¦³¦P¨B¤ÏÀ³¤£¥Î¾á¤ß¡A¥ý¤í±b¡A¤]ÅýÁÙ¨S¤W¨®ªºª©¤Í¦³±q®e¤W¨®ªº¾÷·|¡C ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/6/6 ¤W¤È 09:22:08²Ä 182 ½g¦^À³
|
¨È·à±d³Ìªñº¦´T¨S¦h¤Ö¡A³ºµM³Q¦C¬°Äµ¥ÜªÑ¡A¬ÝµÛADR¤@ª½¤W½Ä¡A²{¦b¥xÆW³oÃäªÑ»ù·|¨ü¨ì¤À½L¥æ©ö¼vÅT¡A¬Ý¨Ó·|³QÀ£½L¦n¤@°}¤l¤F¡A¯uªº«Ü¥i±¤¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/6/6 ¤W¤È 09:18:28²Ä 181 ½g¦^À³
|
ÁÂÁ¤ѩR¤j³o°}¤lªº±K¤Á°lÂܤΤÀªR~~ªº½T!!ªø½u»ùÈ¥ÑÁ{§É¼Æ¾Úªº¥æ¤e¤ñ¹ï«áªº¦bªvÀøPan-Her+ªº¼ç¤O¤ÎADR/¥xÆWªÑ»ùªº»ù®t´N¥i¥Hª¾¹D~ ¥H¤W¨Ñ°Ñ¦Ò,¤Å·íªÑ²¼¶i¥X°Ñ¦Ò¨Ì¾Ú |
|
|
·|û¡G¥²³Ó«È10144050 µoªí®É¶¡:2018/6/6 ¤W¤È 08:29:39²Ä 180 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j~ ¬OU3-1401ÁÙ¬OU3-1402? |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/6/1 ¤U¤È 10:44:56²Ä 179 ½g¦^À³
|
¦Ñ·à¨üÁÜ°Ñ¥[6/7·ç¤h«H¶U¥D¿ì¤§Greater China Healthcare Corporate Day-ªk»¡·|³ø§i¦p¤U³sµ²: ¤×¨ä¬O²Ä6¤Î13~14¶-GÀù¼ç¦b¯f±w¼Æ(¤ñÁx¹DÀù§ó¦h)¤Î¤G´Á¼Æ¾Ú±N©ó2H18´¦ÅS~ªø½u»ùȤ@¤@¯B²{ mops.twse.com.tw/nas/STR/649720180531M001.pdf ¥H¤W¨Ñ°Ñ¦Ò,¤Å·íªÑ²¼¶i¥X¨Ì¾Ú |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/6/1 ¤U¤È 10:21:07²Ä 178 ½g¦^À³
|
ASLAN PHARMACEUTICALS LIMITED 106¦~¦~³ø¥XÄl 37--50 Àç¹B·§ªp mops.twse.com.tw/mops/web/t57sb01_q5 |
|
|
·|û¡G¥²³Ó«È10144050 µoªí®É¶¡:2018/6/1 ¤W¤È 12:10:25²Ä 177 ½g¦^À³
|
¨È·à±d-KY¬O¤@°¦¨È¬w·à ¤j³¡¤ÀªºªÑÅv³£¦b¥xÆWÂd¶R¥æ©ö ¬ü°êADR¥u¬O¤@¤p³¡¤À §Ú¤]´¿¸gÃö¤ß¹L·à¤l¬ü°êADRªºªí²{ ¦ý«á¨Ó·Q³q¤F ¥xÆWªÑ»ù¤~¬O¼Ð¬ñ ¥~°ê¤H¶R½æ¥x¿n¹qªºADR¤]¬O°Ñ¦Ò¥xÆWªºªÑ»ù ³»¦h¦A¥[¤W¬üªÑÁ`¸gªºªí²{ ©Ò¥H¤£¥Î¦b¥GADRªºªí²{ ¤§«eºâ¹L§â©Ò¦³¨È·à±d-KYªºADR¶R¤U¥u»Ý¥x¹ô10»õ ¦pªG¦³¤H¶R¤U¤@¥bªºADRªÑÅv ¤µ¤ÑÅý¥L¤Wº¦30% ©ú¤ÑÅý¥L¤U¶^30% ¯u¬O©ö¦p¤Ï´x |
|
|
·|û¡Gkenken10138351 µoªí®É¶¡:2018/5/31 ¤U¤È 01:55:02²Ä 176 ½g¦^À³
|
½æ¤Ó¦¤FÂI¡AÂê¤F§Ö¤@¸U±i¡A¨º¨Ç¥h¶RADRªº¤H¡A¥i¤£¬OµL½tµL¬G¥h¶R¡A³£¬O°Ñ¦Ò³o¨Ç³ø§iªº¡Aı±o»{¦P¤~·|¶R¡A³o¨Ç³ø§i³£nªá¿ú¶R¡A¤@¯ë´²¤á¬Ý¤£¨ì¡A¥u¦³°òª÷¸g²z¤H©Î¬O¦³¥I¶Oªº«È¤á¤~¦³¡A©Ò¥H¥hgoogle·íµM§ä¤£¨ì¡C³Ì«áÁÙ¬O¬°±z¥i±¤¤F¡C |
|
|
·|û¡G¥²³Ó«È10144050 µoªí®É¶¡:2018/5/31 ¤U¤È 12:28:45²Ä 175 ½g¦^À³
|
§Ú¤µ¦¤w½æ¤@¥b·à¤l«ùªÑ ¦]¬°·j´M¤£¨ì¥ô¦ó¹ê½è§Q¦h ¥u¦³´CÅé³Û»ù½Õ°ª¥Ø¼Ð»ù ¤H¬°ª£§@¦¨¥÷©~¦h ¤µ¤Ñ¤S³{¤ë©³¥~¸ê§@±b «ç»ò¤W¥h´N«ç»ò¤U¨Ó ¦pªG©ú¤Ñ¦¤WADR³Q¥´¦^ì§Î ¤£´NGG¤F |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/5/31 ¤W¤È 08:49:29²Ä 174 ½g¦^À³
|
«z~~¤j®a³£¦^¨Ó¤F,¬Ý¨Ó¥«È·|¨ì¦h¤Ö¤j®a¤ß¸Ì³£¦³ÃФF~~Ä~Äò¥[ªo |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/31 ¤W¤È 08:31:40²Ä 173 ½g¦^À³
|
ÁÂÁ²q·Q¤j¤jªº¹ªÀy¡A´Á¬ß¦³¼ç¤Oªº¥Í§Þ¤½¥q³£¯àÀò±oÀ³¸Ó¦³ªº»ùÈ¡AÅwªï¤@°_¬ã¨sµo±¸¦³¼ç¤Oªº¥Í§Þ¤½¥q¡C |
|
|
·|û¡GKO10139074 µoªí®É¶¡:2018/5/31 ¤W¤È 08:08:23²Ä 172 ½g¦^À³
|
¦hÁÂ¥xÁÞ¤j¤Î²³¤jªº¤À¨É ±µµÛ´N¬OASCO¦~·|µoªí¡A¬Ý¨Ó³vº¥¬Ý¨ìÀÆ¥ú¤F |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2018/5/31 ¤W¤È 06:29:58²Ä 171 ½g¦^À³
|
¥xÁÞ¤j¤j ·à¤ÍÌ ®¥³ß¤F ¥XÀY¤Ñ¤F finance.yahoo.com/quote/ASLN/ ASLAN Pharmaceuticals Limited (ASLN) NasdaqGM - NasdaqGM Real Time Price. Currency in USD 9.21+2.36 (+34.45%) At close: 4:00PM EDT 9.10 -0.11 (-1.19%)66 After hours: 5:50PM EDT |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/30 ¤U¤È 11:40:38²Ä 170 ½g¦^À³
|
¦nªÑ¤£·|±I¹æ ¤Ñ©R¤j ÁÂÁ Åwªï¤@°_¬ã¨s·à¤l ÁÂÁÂKenken ¤j´£¨Ñ´^³ÕªÀ³Ì·s¸ê°T ( ¤j´T½Õ°ª Asln ADR ¥Ø¼Ð»ù) www.marketwatch.com/investing/stock/asln ±q Arqule ¤G½uÁx¹DÀù±ÂÅv¨óij§Ú¬Ý¨ì¨È·à±d ASLAN 001 ªº»ùÈ»P¼ç¤O 1 ³oÁûÃľA¥Î¨x¤ºÁxºÞÀù FGFR ¬ðÅÜ ( 40% -50% X 10% -20% = 4% -10% ) ¦û Áx¹DÀù10% ¥H¤U ¨È·à±d ASLAN 001 ¾A¥ÎÁx¹DÀù¤H¤f¦û¤ñ60% - 70% 2 derazantinib 2021 ¦~¤~·|§¹¦¨Á{§É¸ÕÅç ASLAN 001 2018 ¦~©³¤½§i¤¤°êÁ{§É¸ÕÅç¼Æ¾Ú 2019¦~²Ä¤@©u ¤½§i¥þ²y¼Ï¯Ã¸ÕÅç¼Æ¾Ú, 3¨È·à±d¤£¦ý¬O²Ä¤@®a¦b¬ü°ê±¾µPªº¥xÆW¥Í§Þ¤½¥q,¤]¦³«Ü¤j¼ç¤O¦A³Ð°ê¤º±ÂÅvª÷·s°ªªº¥xÆW¥Í§Þ¤½¥q 4 §Ú¬Ý¨ì¨È·à±dªº»ùÈ»P¼ç¤O ( ÁÙ¦³«æ©Ê°©Åè©Ê¥Õ¦å¯f¤G´Á¼Æ¾Ú GÀù¤G´Á¼Æ¾Ú ¤]±N¦b¤U¥b¦~¤½§i ) 5 ADR»ù®æ¤W¤W¤U¤U¬O·n®Ìªº¼v¤l,¦³¦nªº¼Æ¾Ú¤~¦³¦nªºADR »ù®æ ,¤]¤~¦³¦nªº±ÂÅv©Î¨ÖÁÊ»ù¿ú,¯à©µÄò¥¼¨Ó¤Q¦~¬ãµo¸g ¶O¤£¯Ê ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò ,½Ð¤Å·í¨Ì¾Ú¬°§ë¸ê |
|
|
·|û¡Gkenken10138351 µoªí®É¶¡:2018/5/30 ¤U¤È 11:17:09²Ä 169 ½g¦^À³
|
(Bloomberg) -- BTIG LLC initiated coverage of Aslan Pharmaceuticals Ltd.¡¦s American depository receipts with a recommendation of buy. PT set to $16, implies 134% increase from last close. Aslan Pharmaceuticals average PT is $14.50 Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) received a Buy rating and a $12 price target from H.C. Wainwright analyst Ram Selvaraju today. The company¡¦s shares closed yesterday at $6.85, close to its 52-week high of $6.94. |
|
|
·|û¡Gkenken10138351 µoªí®É¶¡:2018/5/30 ¤U¤È 11:12:17²Ä 168 ½g¦^À³
|
(Bloomberg) -- Leerink Partners LLC initiated coverage of Aslan Pharmaceuticals Ltd.¡¦s American depository receipts with a recommendation of market perform. PT set to $7, implies 2.2% increase from last close. Aslan Pharmaceuticals average PT is $12 |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/5/30 ¤U¤È 02:53:37²Ä 167 ½g¦^À³
|
³o¨â¤Ñ·Pı¬O¥xÆWº¦±a°ÊADRº¦¡A¤µ¤Ñ¥xÆW³oÃä¤S¨ü¨ìADRªº¼vÅTÄ~Äò©¹¤W½Ä¡A¤£¹L¥Ø«e·Pı¥xÆW³oÃ䪺§ë¸ê¤H¤ñ¸û¬Ý¦n¡A¦³¦n´X¤Ñ³£¬OADR¶^¡A¦ý¬O¥xÆW³oÃ亦¡AÁÙ¬O§Æ±æ»°§Ö¨È·à±d¯àºÝ¥X¤@¨Ç¦¨ªG¡AÅýADR±a°Ê¥xÆWªºªÑ»ù©¹¤W½Ä! |
|
|
·|û¡GRock10135634 µoªí®É¶¡:2018/5/30 ¤W¤È 09:52:12²Ä 166 ½g¦^À³
|
¬Q¤Ñ¥xªÑ¥ý©Ô§À½Lº¦°± ±µµÛ±ß¤WADR´N¤jº¦¤F¡A¤]¨S¦³¥ô¦ó®ø®§µo§G |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/30 ¤W¤È 08:31:15²Ä 165 ½g¦^À³
|
¦³¤Hª¾¹D¨È·à±d¬ü°êADR¬°¦ó¤jº¦? finance.yahoo.com/quote/ASLN?ltr=1 |
|
|
·|û¡Gª£¦Ì¯»10146792 µoªí®É¶¡:2018/5/29 ¤W¤È 11:09:44²Ä 164 ½g¦^À³
|
¤§«e¨â¦ì§ëÅU¬Oµ¹¤©¤¿ªºµû»ù¡A¦ý¨Æ»PÄ@¹H¡A«á¨ÓºG¶^¡Aarql¤Ï¦Ó¥û²rªºº¦¤W¥h¡A©Î³\¬O¦Ñ·àªºµL¤j¼tÀ°§U¾P°âºÞ¹D¯à§_²£¥Í»ùȳQ½èºÃ§a |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/5/29 ¤W¤È 09:27:33²Ä 163 ½g¦^À³
|
¥Ø«eARQL(»P¦Ñ·àªºÃĦPÄÝÁxÀù½d³ò,·Ó²Î¤@ÃÒ¨éµû¦ô¦Ñ·àÁ{§É¶i«×À³·|¤ñ¥L§Ö)¦b¬ü°ê¥«È¤w¹F5.60»õ¬ü¤¸,Y¬O¦p¦¹¦Ñ®vªº¥«ÈÀ³¸Ó¦h¤Ö¤~¦X²z?¤£ª¾¦U¦ì¤j¤j¦³µL°ª¨£¥i¨Ñ¤À¨É ? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/23 ¤U¤È 11:38:08²Ä 162 ½g¦^À³
|
©t¨àÃĤj¨£¸Ñ¿W¨ì ©ú¹î¬î²@ ¨È·à±d ¦b 2018 06 03 ASCO µoªíªº¨ÅÀùºKn¤w»¡ªº«Ü²M·¡¤F ,·|¬ã¨sÁp¦X¥ÎÃÄ: Varlitinib + ¶PÀù¥ + P ¤]´N¬O V + T + P ¯E¹© ·à¤l¤µ¦~¶Ò¸ê§¹¦¨ ±N¦¨¬°°ê¤º¨â®a²{ª÷»È¼u¥R¨¬ªº¥Í§Þ¤½¥q, ±ÂÅv»P¨ÖÁʽͧPÄw½X¤j¼W, ¯E¹©¥H¤T³±©Ê¨ÅÀù¬°¹ï¶H»P·à¤l¥HHER2+¨ÅÀù ¬°¹ï¶H ( ¤£½Ä¬ð ) ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò,½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú ¨È·à±dªÑ¥÷¦³¤½¥q2018¦~ªÑªF±`·| 2017 ¦~«×Àç·~³ø§i®Ñ ( Á{§É³¡¤À) ( ¸ê°T¨Ó·½: ¤½¶}¸ê°TÆ[´ú¯¸) ¦U¦ìªÑªF¤k¤h¡B¥ý¥Í: ¨È·à±d¦b 2017 ¦~¨ú±o«¤j¶i®i¡A¶¶§Q¦¨¬°°Ó·~¤Æ¶¥¬qªº¥Í§Þ¤½¥q¡A¥»¤½¥q¥Ø«e¦@¦³¤T¶µ¼Ï¯ÃÁ{ §É¸ÕÅ祿¦b¶i¦æ¤¤¡A¨Ã©óªñ´Á«Å¥¬¨ä¤¤¶i®i³Ì§Ö¡B©ó¤¤°ê¤j³°¶i¦æ¤§¸ÕÅç¶i«×¶W¥G¥ý«e¹w´Á¡A¹w p¥i´£«e¦b 2018 ¦~©³¶i¦æ¼Æ¾Ú¤ÀªR¡C¬°¦]À³¤W¥«¶i«×´£«e¡A¥»¤½¥q¤wµÛ¤â¦b¤¤°ê¤j³°¦¨¥ß¾P°â ³¡ªù¡A¤¤°ê¤j³°¹wp±N¦¨¬°¥»¤½¥q²Ä¤@ÓÃĪ«¤W¥«ªº¥«³õ¡A¤é«á¥ç·|±N¨B¤J§¹¦¨¶¥¬q¤§¥þ²y©Ê¼Ï ¯Ã¸ÕÅç¡A©Ý®i¦Ü¬ü°ê¥«³õ¡C¨È·à±d¤µ¦~»P Array Ãļt«·sñq±ÂÅv¦X¬ù¡A¨ú¥Nì©ó 2011 ¦~ñq¤§ ¦X¬ù¤º®e¡A¦V Array Ãļt¨ú±o¨È·à±d¥DnÔ¿ïÃĪ« varlitinib ªº¥þ²y°Ó·~¤Æ©Ò¦³Åv¡A¬°¤é«á¤½¥q°Ó ·~¤ÆÂ૬³þ©w°ò¦¡C¥»¤½¥q¥ç©ó¤µ¦~©e¥ô Stephen Doyle ¾á¥ô¨È·à±d¤¤°êÁ`¸g²zº[°Ó°È°ÆÁ`µô¡A Doyle ¥ý¥Í´¿¾á¥ô°ê»Úª¾¦WÃļt Sanofi (ÁÉ¿Õµá) »P Boehringer Ingelheim (¦ÊÆF¨Î®ï®æ¿«) ¦b¤¤°ê¤j ³°ªº¸~½F³¡ªùt³d¤H¡A¨Ã±À°Ê¹L¦h¶µ·sÃĤW¥«¡A¥¼¨Ó¥ç±N¨ó§U±À°Ê varlitinib ©ó¤¤°ê¤j³°¤W¥«¤§¬Û Ãöpµe¡C ¨È·à±d¤]¦b¨ä¥L²£«~¶µ¥Ø¤W¨ú±o¶i®i¡A¥H½T«O²£«~²Õ¦Xªº¶}µo·ÀI¥¿Å¡AASLAN003 °w¹ï«æ©Ê°©Åè ©Ê¥Õ¦å¯f¬ã¨s¤w¶i¤J¤G´Á¡A¦Ó ASLAN004 ±N¶i®i¦Ü¥Ó½ÐÁ{§É¸ÕÅç¼f¬d (IND) ©Ò»Ý¤§¬r²z©Ê¸ÕÅç¡C ¬°¤ä«ù¥H¤W·s¸ÕÅ窺«ùÄò¶i¦æ¡A¨È·à±d©ó 2017 ¦~ 6 ¤ë 1 ¤é¦bÃÒú³ÂdÂi¶R½æ¤¤¤ß§¹¦¨º¦¸¤½¶}µo ¦æ¡A¶Ò±o·s»O¹ô 10 »õ¤¸¤§¸êª÷¡A¦¨¬°²Ä¤@®a¦b»OÆW±¾µP¤WÂdªº¥~°ê¥Í§Þ¤½¥q¡C¹L¥h¤@¦~ªÑ²¼¥«³õ ªi°Ê°_¥ñ¸û¤j¡A¥Í§ÞÃþªÑªí²{´¶¹M¨ü¨ì§ë¸ê±¡ºü°·Å¤§¼vÅT¡C¥»¤½¥q±N«ùÄòP¤O¬°ªÑªF³Ð³yªø´Á »ùȨúɤO»P§ë¸êªÌ«O«ù¨}¦n¤§·¾³qºÞ¹D¡C ¨È·à±d¥Ñ°J·PÁ¦U¦ìªÑªF¹ï©ó¥»¤½¥qªº«H¥ô¡A¥H¤Î¦U¦ìªÑªF¹L¥h¤@¦~¨Ó¹ï¥»¤½¥qªº¹©¤O¤ä«ù¡C ¤@¡B 2017 ¦~Àç¹B¦¨ªG ²£«~¬ã¨sµo®i·§ªp Varlitinib ¨È·à±d¤µ¦~ºn¤§°È¬°±À°Ê varlitinib Áx¹DÀù»PGÀù¶i¤J¼Ï¯Ã¸ÕÅ綥¬q¡CÁx¹DÀù²Ä¤G½u¤T ´Á¥þ²y©Ê¼Ï¯Ã¸ÕÅç TreeTopp ¤w©ó 6 ¤ë¶}©l©Û¦¬¯f±w¡A¥»¸ÕÅç¦@±N©Û¦¬ 120 ¦ì¯f±w¡A¦p¼Æ ¾Ú¥¿±¡A¥»¤½¥q±N¥H¦¹¸ÕÅçµ²ªG§@¬°¬ü°ê¤Î¥þ²y¨ä¥L¦a°Ï¥Ó½ÐÃÄÃÒ¤§¨Ì¾Ú¡C¤µ¦~ 8 ¤ë¡A ¥»¤½¥q¤½¥¬GÀù²Ä¤@½u¤G/¤T´Á¥þ²y©ÊÁ{§É¸ÕÅç¶}©l©Û¦¬¯f±w¡A²Ä¤G´Á±N©Û¦¬ 40 ¦ì¯f±w¡A ©ó 2018 ¦~¶i¦æ¸ÕÅç¸ê®Æ¤ÀªR¡C¥»¤½¥q¥ç©ó 2 ¤ë«Å¥¬¤é¥»Áx¹DÀù¤@´ÁÁ{§É¸ÕÅ秹¦¨º¦ì¨ü ¸ÕªÌ¦¬®×¡A¦¹Á{§É¸ÕÅç¥i¯Ç¤J«ez 2018 ¦~¥þ²y©Ê¼Ï¯Ã¸ÕÅç TreeTopp ªº¤@Àô¡C¥t¥»¤½¥q©ó 9 ¤ë»P·s¥[©Y°ê¥ß¤j¾ÇÀù¯g¤¤¤ß¦X§@±Ò°Ê varlitinib º¶µ°w¹ï¨x²ÓMÀù (HCC¡A¨xÀù) ¤§Á{ §É¸ÕÅç¡C 2017 ¦~¡A¥»¤½¥q¤½¥¬ varlitinib °w¹ï²Ä¤G½uÂಾ©Ê¨ÅÀù¤§¤G´ÁÁ{§É¸ÕÅç·s¼Æ¾ÚÅã¥Ü¡AÃĪ« ¹ï¯f±w©Ò®i²{ªº¸~½FÁY¤p¦¨®Ä¸û¼Ð·ÇÀøªk¬°¨Î¡C¥»¤½¥q¥ç¤½¥¬²Ä 1b ´ÁÁ{§É¸ÕÅç¼Æ¾Ú¡A·í ¤¤½T¥ß¤F varlitinib ¦X¨ÖÂù¤ÆÀøÃĪ«¨Ï¥Î®É¤§³Ì¤j@¨ü¾¯¶q¡A¨Ï¨È·à±d±o¥H¦b«áÄòªºGÀù ¥þ²y©Ê¼Ï¯Ã¸ÕÅ礤¨Ï¥Î¦¹¤@ªvÀø¤è®×¡C ¨È·à±d©ó¤µ¦~«×¦h¶µ«n¸~½FÂå¾Ç·|ij¤¤¶i¦æ²³ø¡A¥]¬A¬ü°êÁ{§É¸~½FÂå¾Ç·| (ASCO) ¤Î ¼Ú¬wÁ{§É¸~½F¾Ç·|¤§¨È¬w¤j·| (ESMO)¡A¥»¤½¥q¤§²Ä¤G´Á¨ÅÀù¬ÛÃöºKn®ü³ø¥çºaÀò ESMO ²¾ÂàÃþ¨ÅÀù¤§³Ì¨Î®ü³ø¼ú¡C ASLAN003 ASLAN003 ¤§ªvÀø»â°ì³vº¥¦¨¬°¸~½FÂå¾Ç¤¤ªº¼öªù»â°ì¡A¼Æ®a¥Í§Þ¤½¥qµÛ¤â¶}µo DHODH §í¨î¾¯¡A¦ý¶i«×¸¨«á ASLAN003¡C¤µ¦~¥»¤½¥q«Å¥¬Á{§É«e¸ÕÅç¼Æ¾ÚÅã¥Ü ASLAN003 ¥i¾A¥Î ©ó«æ©Ê°©Åè©Ê¥Õ¦å¯f¡A¶i¦Ó»P·s¥[©YÀù¯g¬ì¾Ç¬ã¨s©Ò (CSI)¡B·s¥[©Y°ê¥ß¤j¾Ç Àù¯g¤¤¤ß (NCIS) ¦X§@¡A±N²`¤J±´°Q ASLAN003 ©ó¦å²GÀù¯gªºªvÀø¼ç¤O¡A¨Ã©ó 11 ¤ëÀò±o±Ò°Ê«æ©Ê°© Åè©Ê¥Õ¦å¯f¤G´ÁÁ{§É¸ÕÅ礧®Öã¡A¹wp±N©ó 2018 ¦~µy±ß±o¨ì´Á¤¤¼Æ¾Ú¡C ASLAN004 ¥»¤½¥q¤w©ó¤µ¦~±Ò°Ê¥Ó½ÐÁ{§É¸ÕÅç¼f¬d (IND) ©Ò»Ý¤§ GLP ¬r²z¸ÕÅç¡A¥Ø«e¥¿¬°¹wp¦b 2018 ¦~µy±ß®i¶}ªº²Ä¤@´Á¸ÕÅç·Ç³Æ¬ÛÃö¸ê®Æ¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/5/23 ¤W¤È 11:12:33²Ä 161 ½g¦^À³
|
ÁÂÁÂ¥x¿}¤jªº¸Ô²Ó¤ÀªR~~ §Úªº²L¨£¬OAS0001+Paclitaxel+Carboplatin-2´Á¼Æ¾ÚY¬O¹F¼Ð,´N¾Ö¦³±j¦Ó¦³§QªºÄw½X»P¤j¼t¸û¶q©Î¦X§@(²¦³ºHer+MBC¨ÅÀù¥ÎÃĬO¤jÃÄ),¦]¬°: TrastuzumabyªýÂ_Her2-ù¤óÃļt Pertuzumab ªýÂ_HER2/HER3-ù¤óÃļt AS0001 ªýÂ_©Ò¦³ªxHER®a±Ú-¦Ñ·à ¦Ñ·à¥i¸òù¤óÃļt¦X§@,¤]¥i¸ò¨ä¥L¤j¼t¦X§@·mù¤óªº¦a½L~~«ç»òª±³£¤£·|¿é ¥H¤W¨Ñ°Ñ¦Ò~~~ |
|
|
·|û¡Gª£¦Ì¯»10146792 µoªí®É¶¡:2018/5/22 ¤U¤È 04:16:17²Ä 160 ½g¦^À³
|
ADRªº¼W¸ê³¡¤À¥H©ó¤W¶g¦X¨Ö¤J¥xªÑ¡A¬G¥~¸ê¤ñ¨Ò¼W¥[¡A¥Ø«e·à·à¯uªº¤£¤Ó§®¡AADR¤@ª½³QÀ£¨î6.2¬ü¤¸¥H¤U¡A¤ÏÆ[arql¤@ª½¨gº¦¡A6¤ëªìªº¥Í§Þµoªí§¹¥þ¨S¤ÏÀ³¦ÜªÑ»ù¡A¥i¯àn¥ð®§«D±`¤[ |
|
|
·|û¡G¥²³Ó«È10144050 µoªí®É¶¡:2018/5/22 ¤U¤È 03:08:54²Ä 159 ½g¦^À³
|
§Ú¤U³æªº¨é°ÓAPP¤W±ªº¸ê®Æ ·à¤lªº¥~¸ê«ùªÑ ¦Û16¤é¦Ü¤µ ´N¤@ª½Åã¥Ü¦Ê¤À¦Ê«ùªÑ 15¤é¤§«e³£¬O¦Ê¤À¤§82 ¤£ª¾¹Dµo¥Í¤°»ò¨Æ¤F |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/21 ¤U¤È 11:49:49²Ä 158 ½g¦^À³
|
©t¨àÃĤj A 2018 ASCO : Dose finding study of varlitinib ¡Ó trastuzumab with carboplatin/paclitaxel in advanced solid tumors. This is a phase 1b dose confirmation study to determine safety and early efficacy signals of V ¡Ó T combined with weekly P 80mg/m2 and C AUC = 2 2018 06 04 ASCO ¬ã¨sµoªí µ²½×¬Ý¥X weekly V ¡Ó T combined with P 80mg/m2 and C AUC = 2 µo²{¥[¶PÀù¥¬O¦w¥þªº , Aslan 001 ¦b±ÀÂ˾¯¶q¤U»P¤Ó¥¬vµµ§ü¾J¹ï HER2 ¶§©Ê¨ÅÀù¬O¦³®Äªº , ·Ç³Æµû¦ô¤T¦X¤@§@¬°·s»²§UÀøªk Conclusions: The RD of V combined with P is 300mg BD int, and is active in HER2+ MBC; T can be added safely. The triple combination will be evaluated as neoadjuvant therapy in HER2+ breast cancer B 1/2 ´ÁÁ{§É¸ÕÅç : Official Title: Phase Ib Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by an Open-label Phase II Study in Patients With Stage I-III HER2 Positive Breast Cancer Study Start Date : March 2015 Estimated Primary Completion Date : March 2018 Estimated Study Completion Date : March 2019 1½T©w³Ì¨Î¾¯¶q 2 ¥i¥H¦w¥þ»P¶PÀù¥Áp¦X¥ÎÃÄ 3 ¬°¥¼¨Ó¤T¦X¤@ÁpÃÄ·s»²§UÀøªk«ü¥X¤è¦V (¬O§_¦³¨ú¥N¶PÀù¥ªº¼ç¤O»Ý¶i¦æÁ{§É¸ÕÅç ¤@¨B¤@¨B¦V«e¨«) 4¬O¤£¬O´Á¤¤¤ÀªR§Ú¤£½T©w , ¤Ï¥¿ 2019 3 ¤ë ´N·|§¹¦¨HER2 ¶§©Ê¨ÅÀù¤G´ÁÁ{§É ( ©Û¦¬stage 1 - stage3 ) Drug: Paclitaxel + Carboplatin + ASLAN001 Phase I IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle PO ASLAN001 daily continuously (starting dose 500mg BID) Phase II •PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks Followed by: IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/5/21 ¤U¤È 01:31:16²Ä 157 ½g¦^À³
|
¥xÁÞ¤j,½Ð°Ý³o¦¸¤½§Gªº¼Æ¾Ú¨ä¤¤300mgªº³¡¥÷¯àµø¬°2´Áªº´Á¤¤¼Æ¾Ú¶Ü?§Ú¬Ý³o¹êÅç¬O1,2´Á¦X¨Ö°õ¦æªº ? Ápµ²¦p¤U : clinicaltrials.gov/ct2/show/NCT02396108 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/21 ¤U¤È 12:10:54²Ä 156 ½g¦^À³
|
ASLAN001¬O°w¹ï«üHER2¶§©ÊÂಾ©Ê¨ÅÀù«á½uªvÀø¬°¥D¡A²Ä¤G½uªvÀøªºÀø®Ä¥i°Ñ¦Ò¥h¦~©³ªk»¡Â²³ø¡A¨È·à±d¨ÅÀù¬ãµo¥Ø«e»P¯E¹©¤£¤¬¬ÛÄvª§¡A¨È·à±dn®i²{Áx¹DÀù¡AGÀù¡A¨ÅÀùªº¼Æ¾Ú¥H´£°ª±ÂÅvª÷»ù½Xªº¥ø¹Ï¤ß¥O¤H¨ØªA¡C ¥H¤W¨â«h¤À¨É¡A¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¨Ì¾Ú¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/21 ¤W¤È 11:55:41²Ä 155 ½g¦^À³
|
¤»¤ë¥|¤énµoªíªº Her2¶§©ÊÂಾ©Ê¨ÅÀù«á½uªvÀøªº¼Æ¾Ú·¥¦³¼ç¤O¡]¯f±w¥ý«e¤¤¦ì¼Æ¥Î¤F4½u¡APRÁÙ¦³¦Ê¤À¤§35¡^ºKn¦bµ²½×ªí¹F¤F·|µû¦ôV+P+T ¤TÃÄÁp¦X§@¬°Âಾ©Ê¨ÅÀù·sªº»²§UÀøªk¡C abstracts.asco.org/214/AbstView_214_220585.html |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2018/5/21 ¤W¤È 10:47:39²Ä 154 ½g¦^À³
|
¦U¦ì·à¤Í¤È¦w ³o°}¤l¤u§@¦£¡A¨SªÅºÞ¤â¤¤«ùªÑ ·à¤l¤]¤W¤W¤U¤U¤S¶^¨ì37¥ª¥k (¤§«eªº·¸»ù¤w¸g¦¬ÀĸòADR¤w¸g´X¥G¦P»ù) ¤£ª¾¹D²³·à¤Í¤â¤¤·à¤lªº¦¨¥»§¡»ù¤j·§¦bþ¸Ì? ¤p§ÌÆZ·Q¦b³oÃä°µ¥[½X¡A¤Sı±o§Þ³N±«ÜÁV ¬O»¡§ë¸ê·sÃĤ]¤£¥ÎºÞ¤°»ò§Þ³N±´N¬O |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/5/18 ¤W¤È 10:59:49²Ä 153 ½g¦^À³
|
ªüÁø©j¹ï·à¤lªº¬Ýªk³o¦¸À³¸Ó¬O¹ïªº³á~~³o¦¸ªº2´Á´Á¤¤¼Æ¾Ú³þ©wªvÀøHER+ªº©ú½T¤è¦V,¥[ªo~~·à¤l MBC¼Æ¾Ú:20/37 had HER2+ metastatic breast cancer (MBC) with median 4 (0-14) prior treatment lines. 7 achieved partial response (PR) and 3 stable disease (SD); 6 had disease control with single agent V for a median 7.0 more months (4.3 ¡V 13.3) after chemotherapy ceased. 2/17 with other tumor types achieved PR (HER2- MBC = 1, NSCLC = 1). 3/10 patients (HER2+ MBC = 2) in the V 300mg BD int cohorts achieved PR. No correlation was seen between V and P mean AUC (ng.h/mL) in those with and without DLTs (V 10336.5 vs 20758.8, p = 0.21; P 4882.1 vs 5197.6, p = 0.77). No interaction was seen between V dose/schedule with P PK. Conclusions: The RD of V combined with P is 300mg BD int, and is active in HER2+ MBC; T can be added safely. The triple combination will be evaluated as neoadjuvant therapy in HER2+ breast cancer. ¥H¤W¨Ñ°Ñ¦Ò,¤Å¥H¦¹¬°ªÑ²¼¶i¥X¨Ì¾Ú~~~¥t¥~ÁÂÁÂ¥xÁÞ¤jªº°T®§¤è¦V |
|
|
·|û¡GRock10135634 µoªí®É¶¡:2018/5/18 ¤W¤È 10:18:52²Ä 152 ½g¦^À³
|
«HªüÁø±o®M©Ð ¨C¦¸³£»¡¦³§K¶O¬¡°Ê¯d¨¥´N±a§A¶R¶i·s¼Ðªº µ²ªG²z±M¥´¨Ó´N¬On§A¤J·|û¡A§Ú»¡ªü¤£¬O§K¶O±a¾Þ§@¤@¦¸ µM«á²z¥Ñ¤@°ï§Ú´N±¾¹q¸Ü ¨ä¹ê¤£¬O¯uªºn¸òµÛ¶R¡A¥u·Qťť¥¦Ì¦b·d¬Æ»ò©Û¦Ó¤w |
|
|
·|û¡G¸²µåô10146373 µoªí®É¶¡:2018/5/18 ¤W¤È 08:30:29²Ä 151 ½g¦^À³
|
ªüÁø¬Q¤Ñ»¡¤â¤W¦³¯E¹©¡BÃĵØÃÄ©M¨È·à±dªº »°§Ö¥h§ä¦o ¦o·|À°§A¥þ³¡Ä¹¦^¨Ó Ŧ^§Aªº±m¦â¤H¥Í |
|
|
·|û¡G¥²³Ó«È10144050 µoªí®É¶¡:2018/5/18 ¤W¤È 06:09:26²Ä 150 ½g¦^À³
|
ASLAN PHARMACEUTICALS ADR REP 5 ORD NASDAQ: ASLN 6.24 USD +0.040 (0.65%) 5¤ë17¤é ¤U¤È4:00 [EDT] ¡P §K³dÁn©ú |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/17 ¤U¤È 11:24:23²Ä 149 ½g¦^À³
|
§ó¥¿ Ó¤H±À¦ô¤µ¦~6¤ë¨ì©ú¦~3¤ë¬O·à¤lÁ{§É¼Æ¾Úµoªíªº°ª®p´Á ¤j®aÀ³±K¤ÁÃöª` |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/17 ¤U¤È 11:11:30²Ä 148 ½g¦^À³
|
©t¨àÃĤj ¨È·à±d¬O·s¥[©Y¨Ó¥x¤W¥«ªº¥Í§Þ¤½¥q¡A°ê»Ú¤Æµ{«×¬Û·í¦n¡A¥[¤W³o¦¸¥H¨C³æ¦ì7.03¬ü¤¸§¹¦¨¶Ò¸ê¡A²ü¥]º¡º¡¡A ¤µ¦~ªºAACR. ASCO³£·|µoªí¼Æ¾Ú¡A¥¼¨Ó6-9Ó¤ë¬O¼Æ¾Úµoªí°ª®p´Á¡A¤½¥q¤½§iªº¼Æ¾Ú¡A°ê¤º¥~´CÅé³£·|³ø¾É¡A¦]¬°·à¤l°ê»Ú¤Æµ{«×°÷¡C ¥H¤W¸ê°T ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/5/17 ¤U¤È 02:39:57²Ä 147 ½g¦^À³
|
·s¶i«×¥X²{: 1. »¡©úÁxºÞÀù¿é¯Ã¸ÕÅ礴¦b¶i¦æ 2.µ²¦Xµµ§ü¾J¦X¨ÖªvÀø¦b¨ÅÀùªº¦³®Ä©Ê ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO globenewswire.com/news-release/2018/05/17/1507867/0/en/ASLAN-Pharmaceuticals-to-Present-Two-Posters-on-Varlitinib-at-ASCO.html |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/5/17 ¤W¤È 09:20:23²Ä 146 ½g¦^À³
|
²×©ó¦³¤H¨ü¤£¤F¥hµo¨¥¤F,¥H¤U~~~Æg stocktwits.com/symbol/ASLN ¯u·Q§â¥xÁÞ¤j³o½g½Ķ¦¨^¤å¶K¹L¥h~~¤£¦n·N«ä¥xÁÞ¤j,ɥΤ@¤U~~ ·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/10 ¤U¤È 11:44:12²Ä 136 ½g¦^À³ ±q Arqule ¤G½uÁx¹DÀù±ÂÅv¨óij§Ú¬Ý¨ì¨È·à±d ASLAN 001 ªº»ùÈ»P¼ç¤O 1 ³oÁûÃľA¥Î¨x¤ºÁxºÞÀù FGFR ¬ðÅÜ ( 40% -50% X 10% -20% = 4% -10% ) ¦û Áx¹DÀù10% ¥H¤U 2 «eª÷1000¸U¬ü¤¸ ¨½µ{ª÷ 3.26»õ¬ü¤¸ «eª÷/ ¨½µ{ª÷ 1/32.6 ¦³ÂI°¾§C ªí¥Ü ±ÂÅv¶i¨Óªº¤½¥q±Ä¨ú¤ñ¸û«O¦u ºA«× , «eª÷/ ¨½µ{ª÷ ¤ñ²v¶V°ªªí¥Ü±ÂÅv¶i¨Óªº¤½¥q¹ï³oÁûÃÄ¥¼¨Óµo®i«H¤ß«×¶V°ª 3 ¨È·à±d ASLAN 001 ¾A¥ÎÁx¹DÀù¤H¤f¦û¤ñ70% 4 derazantinib 2021 ¦~¤~·|§¹¦¨Á{§É¸ÕÅç ASLAN 001 2018 ¦~©³§¹¦¨Á{§É¸ÕÅç 5 §Ú¬Ý¨ì¨È·à±dªº»ùÈ»P¼ç¤O 6 ADR»ù®æ¤W¤W¤U¤U¬O·n®Ìªº¼v¤l,±ÂÅv¥X¥h½æÓ¦n»ù¿ú,¯à©µÄò¥¼¨Ó¤Q¦~¬ãµo¸g¶O¤£¯Ê¤~¬O¥»½è 7 ¨È ·à±d¤£¦ý¬O²Ä¤@®a¦b¬ü°ê±¾µPªº¥xÆW¥Í§Þ¤½¥q, ¤]¦³«Ü¤j¼ç¤O¦A³Ð°ê¤º±ÂÅvª÷·s°ªªº¥xÆW¥Í§Þ¤½¥q seekingalpha.com/news/3346036-arqule-licenses-derazantinib-basilea-pharma-327m-shares-9-percent-premarket files.shareholder.com/downloads/ARQL/0x0x952609/7FD86678-3664-476F-A556-8B92F36E9C80/Derazantinib_ARQ_087_FGFR_Inhibitor_-_August_2017.pdf ¥H¤W¨Ñ°Ñ¦Ò,¤Å¥H¦¹¬°ªÑ²¼¶i¥X¨Ì¾Ú~~~ |
|
|
·|û¡G¥²³Ó«È10144050 µoªí®É¶¡:2018/5/17 ¤W¤È 07:44:35²Ä 145 ½g¦^À³
|
ASLAN PHARMACEUTICALS ADR REP 5 ORD NASDAQ: ASLN 6.21 USD −0.040 (0.64%) 5¤ë16¤é ¤U¤È4:00 [EDT] ¡P §K³dÁn©ú |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/16 ¤U¤È 11:56:53²Ä 144 ½g¦^À³
|
¤»¤ë¥H«á·|¦³¨xÀù AML GÀù ¤@½uÁx¹DÀù ¤¤°ê¤G½uÁx¹DÀù ¬ÛÃöÁ{§É¼Æ¾Ú¤½§i ¥Ø«e°ê¤º¥Í¥~§Þ¤½¥q¶Ò¸ê¤£©ö,Leo ¶Ò¸ê§¹¦¨²ü¥]º¡º¡, ½Í§P¹ê¤O¤j¼W °ê¥~ADR¹ï¬ÛÃöÁ{§É¼Æ¾Ú©Î ±ÂÅv, ¨ÖÁʵ¥¤½§i·|µ¹¤©À³¦³ªº¤ÏÀ³, ±`±`¬Ý¨ì°ê¥~¥Í§Þ¤½¥q¤½§iÁ{§É¼Æ¾Ú©Î±ÂÅv ©Î ¨ÖÁʪѻùº¦´TµL¤W ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò,½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú |
|
|
·|û¡GRock10135634 µoªí®É¶¡:2018/5/16 ¤W¤È 11:29:14²Ä 143 ½g¦^À³
|
¦ý§Úı±o¬ü°ê¤H¬Ý¥Í§Þ¤ñ¸û«ÈÆ[ ¬Û¹ï¥xÆW´²¤á¬Ý¥Íp¥uÃö¤ß¦³¨S¦³ÁÈ¿ú¤£¬Ý»·´º ¥xÆW¥Í§ÞªÑ¯uªºº¡¥i¼¦ªº |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/5/16 ¤W¤È 11:14:43²Ä 142 ½g¦^À³
|
Rock¤j, ¤£¯àµo^¤å«°T¡]³o¬O²Î¤@ÃҨ骺»¡ªk°Ú¡^,¥i¥Hµo¤¤¤å°T®§°Ú¡]°£«D¬OµL°T®§¥iµo¡ã¡^¡ã¿U¥xÆW¤~¬O¥DÅéù,ADR¥u¬OªþÄÝ...«¢«¢..¥i¯à¬O§Ú¤@´[±¡Ä@°Ú~~ |
|
|
·|û¡GRock10135634 µoªí®É¶¡:2018/5/16 ¤W¤È 11:03:49²Ä 141 ½g¦^À³
|
¨S¿ìªk¡A¨È·à±dADR¤W¬O¦³25Ó¥æ©ö¤éªº½pÀqÅv ©Ò¥H³o¬q´Á¶¡µLªkµo¥¬¥ô¦ó«¤j°T®§¡A¥u¯àµ¥«Ý6¤ë¤W¦¯«á¬Ý¬Ý¤½¥q¦³µL®ø®§µo¥¬ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/5/16 ¤W¤È 09:42:14²Ä 140 ½g¦^À³
|
To : ¥xÁÞ¤j©Î¦U¦ì¦³¤ßªº¤j¤jÌ~~~ ¥i¥H¨ì¬ü°êªº°Q½×°Ï¸ò¥L̲á²áASLNªº»ùȦó¦b¡H§Úµo²{¬ü°êªº¥L̦n¹³«Ü¦h³£¤£À´©Î¬O¤£ª¾±qþÀò±o¸ê°T¡ã¡ã¥»¨Ó¬O·Q¥Ñ¬ü°ê¢Ï¢Ò¢à±a°Ê¥xÆW»ùÈ,¬Ý¨Ón¥Ñ¥xÆW±a°Ê¬ü°ê¤F.... stocktwits.com/symbol/ASLN ¨Ñ°Ñ¦Ò,¤Å¥H¦¹¬°ªÑ²¼¶i¥X¨Ì¾Ú~~~¥D¤O¤]½Ð§A¦hÀ°¦£¤@¤U³á¡I¡I¡I |
|
|
·|û¡G¥²³Ó«È10144050 µoªí®É¶¡:2018/5/16 ¤W¤È 08:12:41²Ä 139 ½g¦^À³
|
ASLAN PHARMACEUTICALS ADR REP 5 ORD NASDAQ: ASLN 6.25 USD −0.14 (2.19%) 5¤ë15¤é ¤U¤È4:00 [EDT] ¡P §K³dÁn©ú |
|
|
·|û¡G¥²³Ó«È10144050 µoªí®É¶¡:2018/5/15 ¤W¤È 05:37:46²Ä 138 ½g¦^À³
|
ASLAN PHARMACEUTICALS ADR REP 5 ORD NASDAQ: ASLN 6.39 USD −0.11 (1.69%) 5¤ë14¤é ¤U¤È4:00 [EDT] ¡P §K³dÁn©ú |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/5/12 ¤W¤È 10:26:30²Ä 137 ½g¦^À³
|
ÁÂÁÂ¥xÁÞ¤jºëÅPªº¤ÀªR~~»ùÈÁ`·|¦b²ö¦Wªº§QªÅ¤¤²f·Ò¥X¨Ó....¥t¥~5/11¤t´¶ªº¥´À£ÃÄ»ù¬Fµ¦,À³¬O°w¹ï¤¤¶¡°Óªºé«d¤U¤â,À³¹ï©t¨àÃÄ·sÃļvÅT¤£¤j,¦A¥[¤WFDA·sÃļf®Ö¬Ò¦³¥[³tªº¸ñ¶H,°Ñ¦Òºô§}¦p¤U : www.epochtimes.com/b5/18/5/11/n10385655.htm ¨Ñ°Ñ¦Ò,¤Å¥H¦¹¬°ªÑ²¼¶i¥X¨Ì¾Ú~~~ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/10 ¤U¤È 11:44:12²Ä 136 ½g¦^À³
|
±q Arqule ¤G½uÁx¹DÀù±ÂÅv¨óij§Ú¬Ý¨ì¨È·à±d ASLAN 001 ªº»ùÈ»P¼ç¤O 1 ³oÁûÃľA¥Î¨x¤ºÁxºÞÀù FGFR ¬ðÅÜ ( 40% -50% X 10% -20% = 4% -10% ) ¦û Áx¹DÀù10% ¥H¤U 2 «eª÷1000¸U¬ü¤¸ ¨½µ{ª÷ 3.26»õ¬ü¤¸ «eª÷/ ¨½µ{ª÷ 1/32.6 ¦³ÂI°¾§C ªí¥Ü ±ÂÅv¶i¨Óªº¤½¥q±Ä¨ú¤ñ¸û«O¦u ºA«× , «eª÷/ ¨½µ{ª÷ ¤ñ²v¶V°ªªí¥Ü±ÂÅv¶i¨Óªº¤½¥q¹ï³oÁûÃÄ¥¼¨Óµo®i«H¤ß«×¶V°ª 3 ¨È·à±d ASLAN 001 ¾A¥ÎÁx¹DÀù¤H¤f¦û¤ñ70% 4 derazantinib 2021 ¦~¤~·|§¹¦¨Á{§É¸ÕÅç ASLAN 001 2018 ¦~©³§¹¦¨Á{§É¸ÕÅç 5 §Ú¬Ý¨ì¨È·à±dªº»ùÈ»P¼ç¤O 6 ADR»ù®æ¤W¤W¤U¤U¬O·n®Ìªº¼v¤l,±ÂÅv¥X¥h½æÓ¦n»ù¿ú,¯à©µÄò¥¼¨Ó¤Q¦~¬ãµo¸g¶O¤£¯Ê¤~¬O¥»½è 7 ¨È ·à±d¤£¦ý¬O²Ä¤@®a¦b¬ü°ê±¾µPªº¥xÆW¥Í§Þ¤½¥q, ¤]¦³«Ü¤j¼ç¤O¦A³Ð°ê¤º±ÂÅvª÷·s°ªªº¥xÆW¥Í§Þ¤½¥q seekingalpha.com/news/3346036-arqule-licenses-derazantinib-basilea-pharma-327m-shares-9-percent-premarket files.shareholder.com/downloads/ARQL/0x0x952609/7FD86678-3664-476F-A556-8B92F36E9C80/Derazantinib_ARQ_087_FGFR_Inhibitor_-_August_2017.pdf ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ½Ð¤Å·í¬°§ë¸ê¨Ì¾Ú |
|
|
·|û¡GMBE10145047 µoªí®É¶¡:2018/5/9 ¤W¤È 02:25:05²Ä 135 ½g¦^À³
|
1.¨Æ¹êµo¥Í¤é:107/05/08 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ:¨Ì³W©óµo¦æ¤é´Á¤½§i¥»¤½¥q¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ ¤§¬ÛÃö¸ê°T¡C 6.¦]À³±¹¬I:µL 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ¥»¤½¥q¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ¤§µo¦æ±ø¥ó¦p¤U¡G (1) µo¦æ¤½¥q¡G¨È·à±dªÑ¥÷¦³¤½¥q (2) µo¦æºØÃþ¡G²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ (3) µo¦æÁ`ª÷ÃB¡G¬üª÷42,180,000¤¸ (4) µo¦æÁ`¼Æ¡G¹ê»Úµo¦æ³æ¦ì¼Æ¬°6,000,000³æ¦ì¡A¨C³æ¦ì¬ü°ê¦s°U¾ÌÃÒªí¹ü¥»¤½¥q´¶ ³qªÑ5ªÑ¡AÁ`¹ê»Úµo¦æ´¶³qªÑªÑ¼Æ¬°30,000,000ªÑ¡C (5) ¨C³æ¦ìµo¦æ»ù®æ¡G¬üª÷7.03¤¸ (6) ¨CªÑ»ù®æ¡G§é¦X¬°·s»O¹ô¬ù41.72¤¸(«ö¬üª÷§I·s»O¹ô¶×²v=0.03369)¡C (7) µo¦æ¤é´Á¡G107/05/08 (8) ¥æ©ö¦aÂI¡G¨º´µ¹F§JÃÒ¨é¥æ©ö©Ò (9) µo¦æ¦aÂI¡G¬ü°ê (10)¦s°U»È¦æ¡G¼¯®Ú¤j³q»È¦æ (11)q»ù¤é¡G107/05/04 (12)¥»¦¸²{ª÷¼W¸ê°ò·Ç¤é¡G¥»¦¸²{ª÷¼W¸êµo¦æ·sªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ©ó107¦~05¤ë 08¤é¦¬¨¬ªÑ´Ú¡A¨Ãq107¦~05¤ë08¤é¬°²{ª÷¼W¸ê°ò·Ç¤é¡C (13)¸êª÷¹B¥Îpµe¤Î¹wp¥i¯à²£¥Í®Ä¯q¡G¤@¯ë¥ø·~¥Î³~-«·sñq±ÂÅv¦X¬ù¡BÃĪ«¬ãµo ¤Î°Ó«~¤Æ¤Î·sÃĬdÅçµn°O¥Ó½Ð¡A«ez¤T¶µpµe¹wp½Õ¾ã±ÂÅv¥æ©ö¬[ºc¡B¶i¦æ¬ãµo »s³y¬¡°Ê¡BÁʶR±M§Q¡B«Ø¥ß°Ó·~¼Ò¦¡¥H´£¤ÉªÑªF§Q¯q¡C (14)¹ïªÑªFÅv¯q¤§¼vÅT¡G¹wp±N´£¤ÉªÑªF§Q¯q¡Aµo¦æ·sªÑ30,000,000ªÑ¡A¥[p¥Ø«e ¹ê¦¬ªÑ¥»130,128,940ªÑ¡A¨ä¨CªÑµ|«e¬Õ¾lµ}ÄÀµ{«×18.73%¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/8 ¤U¤È 11:46:16²Ä 134 ½g¦^À³
|
¤µ±ßÆZ±jªº¡AADRº¦´T§Ö¹Gªñ¦Ê¤À¤§12 www.marketwatch.com/m/quote/asln |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/5/8 ¤W¤È 10:09:55²Ä 133 ½g¦^À³
|
«¥Ì³o¨Ç°Q½×ª©,«Ü¦h¥D¤O³£·|¨Ó³oÃäÆ[¹î°Ê¦V,Äw½X¥L¤ñ§Ú̦æ,¦ý°ò¥»±ªº¤ÀªR©Î³\¬O§ÚÌ¥i¥H¬ð¯}ÂI~~¥[ªo |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/5/8 ¤W¤È 08:58:00²Ä 132 ½g¦^À³
|
¤µ¤Ñ¨S·N¥~À³¸Ó¤S¬O¤@®Ú¶^°±¡AADR²Ä¤G¤ÑÁÙ¬O¨«¶^¡AÁöµM¶^¶ÕÁͽw¤F¡A¥u¦³¶^2%¦h¡A¦ý¬O«e¤Ñ¶^ªº20%¥[¤W§é»ù10%¡A§Ú¬Ý¥i¯à¯uªºn¦^´ú«e¤@ªi§CÂI30.8¤F¡A°£«D³Ìªñ¦³Ô£¦n®ø®§¤½¥¬¡A§_«hn¤îÃÁÙnµ¥µ¥! |
|
|
·|û¡GJames146310146097 µoªí®É¶¡:2018/5/7 ¤W¤È 11:21:49²Ä 131 ½g¦^À³
|
½Ð°Ý¤p³Á¥S¡A±z©Ò¬Ý¨ìªº¦n®ø®§¬O«üþ¤@¤è±? ³oªi¨È·à±d±q§CÂI¤Ï¼u´N¬OÂǵۦb¬ü°êµo¦æ ADR¡A§Æ±æÂÇ¥ÑADR·¸»ùµo¦æ¥B¤Wº¦¨ì¦X²zªº¤ô·Ç±a°Ê¥xÆWªÑ»ù(·í®É¥«³õ´N¬OÄjº©³o¼Ëªº®ðª^¤~§âªÑ»ù±À¤É¨ì60¥H¤W)¡A²{¦b³o¼Ëªºµo®i¡A¥D¤OÅK©w¤w¸g¨«¤H¡A¦Ó¬Û«H³o¼Ë½×½Õªº´²¤á¡A¥u¯à¤SnW¦u´H½`¡A°£«D¤½¥q·sÃĦ³¬ð¯}©Êªºµo®i¡A§_«h¤j·§¤Sn´ú¸Õ«eªi§CÂI¤F¡C §Æ±æ¤½¥qªñ´Á¯àµoªí¥¿±¬ã¨s¼Æ¾Ú¡AÅýªÑ»ù¤Ï¬M¤½¥q¦bªk»¡·|©Ò´£¨ìªº»ùÈ¡A¤]¥i¬@±Ï¦V¤U¨I²_ªºªÑ»ù©M¦]¬Û«H¤½¥q¤ä«ù¤½¥q«oºG¾D®M¨cªºªÑªFÌ¡C |
|
|
·|û¡G¤p³Á10146801 µoªí®É¶¡:2018/5/7 ¤W¤È 10:40:39²Ä 130 ½g¦^À³
|
©ú©ú¬O¦n®ø®§¡A´CÅé«o¼g±o¦n¹³¦³¦hÁV¿|¨Ì¼Ë |
|
|
·|û¡GJames146310146097 µoªí®É¶¡:2018/5/7 ¤W¤È 10:14:46²Ä 129 ½g¦^À³
|
ì©lªÑªF¦b¥xÆWIPO²Ä¤@¤Ñ¥i¯à´N¤w©ß¥X«ùªÑ¡A¤£µM«ç»ò¥i¯à²Ä¤@¤Ñ´N¶^¯}©Ó¾P»ù¡A¨È·à±dÀ³¸Ó¤½¶}¼á²M¦Û¤v¬O§_¦³ÄY®æ±±ºÞì©lªÑªFªº«ùªÑ¡A¦pªG§Q¥Î¤½¶}¥«³õÄw¸ê(¥xÆW+NASDAQ)¡A«o¤£¬ù§ôì©lªÑªF®M§Q¦æ¬°(¥ý½æ«á¶R)¡A±NÄY«¶Ë®`¨ì·sªÑªFªºÅv¯q¡A¤]§Æ±æ¥DºÞ¾÷Ãö¯à°÷Ãöª`¨ÃªÈ¥¿. |
|
|
·|û¡GJames146310146097 µoªí®É¶¡:2018/5/7 ¤W¤È 10:05:05²Ä 128 ½g¦^À³
|
·Pı³o®a¤½¥q¦b´CÅé³y¶Õªº¤è¦¡¦³°ÝÃD¡A¹L¥h¤@ª½¦Û§Ú·Pı¤Ó¨}¦n¡A³o¦¸¤j®a´Á«Ý¥h¬ü°ê¤ñ»ù¨ú±o¦X²zªºBenchmark¡A µ²ªG·m¥ýµo¦æ ADR «o¸¨±oº¤é¤j¶^ªºµ²ªG¡A¬O§_¾Þ§@ªº¹L©ó«æļ¡A¥t¥~¥~¬É¹ï¨È·à±dªººÃ¼{¡A¬O§_¦³¥R¤À·¾³q¸ÑÄÀ? §Æ±æ¤½¥qµu´Á¶¡¯àÄÀ¥X¸û¥¿±ªº¼Æ¾Ú¡A¥H¤ä¼µ¶^¶^¤£¥ðªºªÑ»ù¡A¦Ü¤Ön¥ýÃ¦í¥«³õ»ù®æ§a¡A§_«h¹ï¤½¥q¥¼¨ÓÄw¸ê±N·|¬OÃø¤W¥[Ãø. |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/5/7 ¤W¤È 10:04:15²Ä 127 ½g¦^À³
|
Ó¤H·PıADR¦b¬ü°ê²Ä¤@¤Ñ¶^20%ÁÙ¬O¦³ÂI¤£¸Ñ¡A°²³]ì©lªÑªFn½æªÑÀ³¸Ó¨S¥²n¦b¬ü°ê½æ§a¡A¦]¬°n§é»ù10$¡A¦ý¬O¥i¥H¦b²Ä¤@¤Ñ´N¯à©ß¥X¨º»ò¦h³f¤£¬O¤]¥u¦³ì©lªÑªF¦³¶Ü? ¬°¦ó¥¦n¦b¬ü°ê½æ©O? Ãø¹D¬O¦]¬°¬ü°ê¨S¦³º¦¶^´T¨î¡A·Qn¤@¤f®ð¥X²M¡A¦]¬°¨S¦³Äw½X¥i¥H¬Ý¡A¤£ª¾¹DADR²Ä¤@¤Ñ¬O½Ö½æªº¡A¥u¬O¦³ÂI·Q¤£³q¦Ó¤w! |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/5/7 ¤W¤È 09:48:48²Ä 126 ½g¦^À³
|
¥¢±æªº¤j½æÀ£¬OÃø§K,«áÄò§Æ±æ¦³§ó¦³¤O¼Æ¾Ú¤Î±¹¬I(¦p±ÂÅv©ÎÀu¶VªºÁ{§É¼Æ¾Ú),¤£µM¥Ã»·«ÁÐ¥h¦~¤W¥«ªºª¬ªp~~²Ö |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/7 ¤W¤È 08:47:29²Ä 125 ½g¦^À³
|
·à¤l¦b¬ü±¾µPªÑ»ùªí²{¤£¦p¹w´Á¬O¤@®Éªº¡A½Öª¾¹D¤µ¤Ñ±ß¤Wªºªí²{¤S·|¦p¦ó?Ó¤H»{¬°³Ì«nªº¬O¨È·à±d²{¦³ªº¸êª÷¥[¤W³o¦¸¦b¬ü°êµo¦æªº¦s°U¾ÌÃҩҶҨ쪺¸êª÷¡AÅý¤½¥q¥i¥H¤@®iªø¤~¡AÅý¥¼¨Ó¦U¶µ¬ãµo¶¶§Q¶i¦æ¡A¦³¨¬°÷ªº²{ª÷¦b±ÂÅv½Í§P©ó¨ÖÁʤW¤]¬O¤@ºØ±j¦Ó¦³¤OªºÄw½X¡C¤£¬O¶Ü? ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡Gª£¦Ì¯»10146792 µoªí®É¶¡:2018/5/5 ¤W¤È 12:45:55²Ä 124 ½g¦^À³
|
ÁöµM©w»ùÅý§ÚÃø¹L¡Aµu´Á·|¦³½æÀ£¯B²{¡A¦ý¬JµM¯à¤ñ¥x·LÅé§ó¦¤W¥«¡A¬Û«H¦¹ªÑ¤ñ¹w¦ô7.46¤¸ªº¥x·LÅé§ó¦³Ãzµo¼ç¤O¡A¥«³õ¼ç¤O¤Î¶i«×¤ñ¬Û¦P²£«~ªºarqule§ó¦n¤]§ó»â¥ý¡A´Á«Ý³æªÑ»ùÈ¥ý¶W¶VArQule,¦A¤ÏÀ³¥XÃÄ«~§ó¤jªº¥«³õ»ùÈ |
|
|
·|û¡Gª£¦Ì¯»10146792 µoªí®É¶¡:2018/5/5 ¤W¤È 12:11:47²Ä 123 ½g¦^À³
|
¨È·à±d«Å¥¬§¹¦¨¬ü°ê¦s°U¾ÌÃÒq»ù ±Mª`©ó¶}µo¨È¬w²±¦æ»P¼Ú¬ü©t¨à¯e¯fÀù¯g¡B¦ì©óÁ{§É¶¥¬q¤§¥Íª«»sÃĤ½¥q¨È·à±d-KY (6497)¤µ¤é«Å¥¬§¹¦¨¬ü°ê¦s°U¾ÌÃÒ(ADS)q»ù¡A¨C³æ¦ì¹ê»Úµo¦æ»ù®æ¬°¬üª÷7.03¤¸¡A¹ê»Úµo¦æ³æ¦ì¼Æ¬°6,000,000³æ¦ì¡A¨C³æ¦ì¬ü°ê¦s°U¾ÌÃÒªí¹ü¨È·à±d-KY´¶³qªÑ5ªÑ¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/4 ¤U¤È 08:31:21²Ä 122 ½g¦^À³
|
6497Ó¤H¬ã§P·|¬O°ê¤º²Ä¤@®a¦b¬ü°ê±¾µP¨Ã¶}©l¥æ©öªº¥Í§Þ¤½¥q¡AÅý¯u¥¿ªº»ùȦb§óÄ£²´ªº°ê»Ú¥«³õ¯u¹êªº¤ÏÀ³ ¥H¤W¤À¨É¡A¶È¨Ñ°Ñ¦Ò ¨È·à±d·sÃĬãµo¶i«×»PADR±¾µP¬ÛÃö¸ê°T½Ð¥H¤½¶}¸êÆ[´ú¯¸¤½§i¬°·Ç |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/4 ¤U¤È 08:15:56²Ä 121 ½g¦^À³
|
¥t¥~½Ð¤j®a·Q·Q¡A¤G½uÁx¹DÀù¨Ì¾Ú¤½¥q¹w¦ô¼ç¦b¥«³õ¦³14»õ¬ü¤¸¡A¤@½uGÀù30»õ¬ü¤¸¡A¥«³õ¼ç¤O¤]¤£¿éµ¹³Ìªñ¶W¶V300ªº4147 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/4 ¤U¤È 07:54:41²Ä 120 ½g¦^À³
|
6497¦b¬ü°êµo¦æADRÁÙì¤@ªÑ¬O1.61¬ü¤¸¡A»P¦P¼Ë¬ãµoÁx¹DÀùªºArqule ¤µ¦¦¬2.63¬ü¤¸¡A¦³1.02¬ü¤¸®t¶Z¡C ¤µ¤Ñ6497°ê¤º¦¬½L¤w¸g§C©ó¹w¦ô¤W¥«»ù(1.61x29.7=xx ¨Ì¾Ú¤½¥q³W¹º¤»¤ë¶}©l¨ì¦~©³¦³¨xÀù¡AAML,GÀù¡A¤¤°êÁx¹DÀù¼Æ¾Ú¤½§i¡Aȱo±K¤Áª`·NADR¶}½L¡C ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡Gª£¦Ì¯»10146792 µoªí®É¶¡:2018/5/4 ¤U¤È 05:36:14²Ä 119 ½g¦^À³
|
www.nasdaq.com/markets/ipos/activity.aspx?tab=upcoming 8.05¤¸¬O¥Î4¤ë¬Y¤Ñ¦¬½L»ù5¿¤Î·í¤é¶×²v¬°¥D ²{¦b¥u¯àµ¥ADR¬O§_¯à¤ÏÀ³¥X°ª©óArquleªÑ»ùªº»ùÈ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/5/4 ¤U¤È 03:46:52²Ä 118 ½g¦^À³
|
³oADRªºµo¦æÀ³¸Ó¬OT+1¤~¹ï,¨ä8.05À³¥u¬O°e¥óªº¹w¦ô»ù....ª©¤WY¦³¤j¤j¤§¨ì§ó¶i¤@¨Bªº°T®§,½Ð¤£§[¤À¨É°Ú~~ ¥H¤W¨Ñ°Ñ¦Ò |
|
|
·|û¡Gkenken10138351 µoªí®É¶¡:2018/4/30 ¤W¤È 09:28:13²Ä 117 ½g¦^À³
|
4/30 Aslan Pharmaceuticals Ltd (ASLN) will issue 7.5 million shares at $8.05 Thursday on the Nasdaq. The Singapore-based biotech develops oncology therapeutics for prevalent diseases in Asia and orphan indications in the U.S. and Europe |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/4/19 ¤U¤È 01:46:50²Ä 116 ½g¦^À³
|
¥i¤ñ¹ï2018.01ªk»¡·|ÀÉ®×»P¥xÁÞ¤jªº¤ÀªR~~§ó¥i¤@¥Ø¤FµM, ¤×¨ä¬O²Ä13¶,»¡©úEGFR/Her®a±Ú¥i¤@¦¸³QVarli§í¨î,ªýÂ_©Ò¦³Her®a±Ú¬ÛÃöÀù¤ÆªºSignal Transdution,³oÃIJzªº½T¦³¬ÝÀY... mops.twse.com.tw/nas/STR/649720171205M001.pdf ¥H¤W¨Ñ°Ñ¦Ò,¤Å·í§ë¸ê¨Ì¾Ú~~~~ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/4/18 ¤U¤È 11:33:47²Ä 115 ½g¦^À³
|
©t¨àÃĤj Ó¤H¥h¦~9¤ë¥ª¥k¶}©l¬ã¨s¨È·à±d¬O·Q§@§ë¸ê²Õ¦X, ÁöµM§ë¤J¸êª÷¤£¦h, ÁöµM«Ü¦h¤H¶]¥ú¥ú, ªO±¦³ÂI§N...... ¨È·à±d´±¥h¬ü°êµo¦æADRªí¥Ü¨ä°]°È°·¥þ, °ê»Ú¤Æªº¥ø¹Ï¤ß°÷, ³o®a¤½¥q³ºµM´±°µ³æÃÄÀø®ÄÁ{§É¸ÕÅç¥YÅã¹ïÃĪ«¾÷¨î¦³«H¤ß,¸Û¦p©t¨àÃĤjª©ÀY¼ÐÃD:°È¹ê¥B¦³¼ç¤Oªº·sÃĤ½¥q , ³o®a¥Ñ¥~¸ê¦¨¥ßªº¥Í§Þ¤½¥q¦p¦ó¦bÀù¯g¬ãµo¹D¸ô¤W¥H¨äÆF¬¡ªºµ¦²¤ ²æĹ¦Ó¥X, ¤j®a´N«ø¥Ø¥H«Ý ¨È·à±d±N¦b¬üÀù¯g¬ã¨s¨ó·|µoªí·s¸ÕÅç¼Æ¾Ú ¨È·à±dªí¥Ü¡AVarliti 2018 ¦~ 4 ¤ë 17 ¤é¡A·s¥[©Y¡V±Mª`©ó¶}µo¨È¬w²±¦æ»P¼Ú¬ü©t¨à¯e¯fÀù¯g¡B¦ì©óÁ{§É¶¥¬q¤§¥Íª«»sÃĤ½¥q¨È·à±d -KY (6497)¤µ¤é«Å¥¬¡A±N¦bªÛ¥[ôÁ|¦æªº 2018 ¦~¬ü°êÀù¯g¬ã¨s¨ó·|(AACR)¦~·|¤Wµoªí varlitinib ªvÀø¨x²ÓMÀù ¤§·s¸ÕÅç¼Æ¾Ú¡C aslanpharma.com/app/uploads/2018/04/180417_Press-Release_ASLAN-presents-at-AACR-CH.pdf Ó¤Hµû½×, ¶È¨Ñ°Ñ¦Ò 1¤½¥q2018¦~³W¹º: ( ¨Ì¾Ú2018¦~¤@¤ëªk»¡Â²³ø) GÀù2´Á¸ÕÅç¸ê®Æ¤ÀªR •¤¤°ê²Ä¤G½uÁx¹DÀù¸ÕÅç¸ê®Æ¤ÀªR •²Ä¤@½uÁx¹DÀù2´Á¸ÕÅç¸ê®Æ¤ÀªR •°Ï°ì©Ê¦X§@¥æ©ö®× ASLAN003 •«æ©Ê°©Åè©Ê¥Õ¦å¯f2´Á¸ÕÅç¸ê®Æ¤ÀªR •°Ï°ì©Ê¦X§@¥æ©ö®× ASLAN004 •1´ÁÁ{§É¸ÕÅç¡A§¹¦¨º¦ì¨ü¸ÕªÌ¦¬®× 2019 Varlitinib ¦b¦U¤j¥Dn¥«³õ´£¥XÁx¹DÀùÃÄÃҥӽР2¨È·à±d¤w©ó2017 ¦~ 9 ¤ë 7 ¤é±Ò°Ê VARLITINIB ©ó¨x²ÓMÀù(HCC)¤§º¶µÁ{§É¸ÕÅç ( 1b/2 ´Á) ¥¼¨Ó³oÁûÃĦb¬ü°ê¤]¬O»PGÀù¤@¼Ë¬O©t¨àÃÄ ( ¦ý¦b¨È¬w³£¬O¤jÃÄ) 3 ·s¥[©Y°ê¥ß¤j¾Ç¬O¨È¬w±Æ¦W²Ä¤@ªº¤j¾Ç , ·s¥[©Y°ê¤jÀù¯g¤¤¤ß§ó¬O¦W´°ê»Ú www.nuh.com.sg/wbn/slot/u3917/NUHcorporate_Chinese.pdf 4 ¨È·à±dµu´Á»ùÈÓ¤H»{¬°¬OASLAN 001Áx¹DÀù (¼Ï¯Ã¸ÕÅç) 5 ¨È·à±d¤¤´Áªº»ùÈÓ¤H»{¬°¬OASLAN 001 GÀù( ²Ä¤G/¤T´Á¸ÕÅç ¼Ï¯Ã¸ÕÅç) »P ¨xÀù( 1b/2´Á) , ASLAN 003 «æ©Ê°©ÀH©Ê¥Õ¦å¯f ( ¤w¶i¤J¤G´Á) ¨ÅÀù( ¤G´Á) »P ¤j¸zÀù ( ¤G´Á) 6 ¨È·à±dªø½uªº»ùÈÓ¤H»{¬°¬OASLAN 004 ¹L±Ó®ð³Ý »P ASLAN 001 aslanpharma.com/zh/pipeline/ 7 ²Î¤@§ëÅUªñ´Á¦³µû¦ô¨È·à±d¥¼¨ÓASLAN001 Áx¹DÀùÁ`±ÂÅvª÷¹w¦ô°Ï¶¡¡A¦X²zÁ`¥«È¦³«D±`±M·~µû¦ô¡A¦p¯à§â¥i¯à¦b¤G´ÁÁ{§É±ÂÅvªºASLAN003«æ©Ê°©Åè©Ê¥Õ¦å¯f( °Ñ¦Ò2018¦~1¤ëªk»¡·|),(ASLAN004¹L±Ó®ð³Ý»PASLAN001»P¨xÀù¤]¦C¤Jµû¦ô´N§ó§¹³Æ¤F 8 ¦Ü©ó¦ó®É·|±ÂÅv¡AÁ`±ÂÅvª÷¬O¦h¤Ö¡A¦b¨S¦³Â½µP«e¡A¨S¦³¤H·|ª¾¹D¡A±ÂÅvªº¤½§i³£¬O¦b¤j®a·N·Q¤£¨ìªº±¡ªp¤Uµo¥Í¡C ¥H¤WÓ¤H¤À¨É¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/4/18 ¤W¤È 09:39:58²Ä 114 ½g¦^À³
|
ÁÂÁÂ¥xÁÞ¤j«ü¤F¤@±ø·s»D©ú¸ô~~¨ä¹êADRªºµo¦æÁÙ¬O¦hµ¹¤F¤j¤á¦A¤@¦¸«·sµû»ùªº¾÷·|,¤W¥««eªº»¡©ú·|´X¥G³£¬O¬°¤j¤áªk¤H¾÷ºc©Ò¶}ªº©O~~~¨ì©³¬O¥ý¶R¥x¤W¥h«á°ª½æA©Î¬O¥ý½æ¥x«á§C¶RA¦A©Ô©ïA,³£¦³¥i¯à~~~ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/4/15 ¤U¤È 10:08:28²Ä 113 ½g¦^À³
|
·j´M¬ÛÃö¸ê°T¥H´£¨Ñ¦Û¤v¿W¥ß§PÂ_¤§°Ñ¦Ò ¨È·à±d¥x·LÅé±Ò°ÊADR±¾µP À禬§Q¦hӪѪí²{¨Î |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/4/9 ¤U¤È 06:55:52²Ä 112 ½g¦^À³
|
MBE¤j, ¦Ñ·àºCºC¨«¥X¥¦ªº»ùÈ, ¥ý¨«¦V¥«È¦Ê»õÀ³¦³¯q©óADRµo¦æ©w»ù~~¥[ªo |
|
|
·|û¡GMBE10145047 µoªí®É¶¡:2018/4/3 ¤W¤È 11:49:03²Ä 111 ½g¦^À³
|
©t¨àÃĤj, ¥h¦~¬Ý±z¶}ª©«á,¶}©l¬ã¨s³o®a¤½¥q ·sÃĪѤ¤¸Î¤w¨úÃÒ,ÃĵØÃÄ¥u³Ñ®É¶¡°ÝÃD ¥¼¨ÓÓ¤H¬Ý¦n¨È·à±d¤Î¥_·¥¬P¦¨¥\¾÷²v¸û°ª ÁöµM¥Ø«e¤wµL«ùªÑ,¤´·PÁ±zªø´Áªº°lÂܤΤÀ¨É |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/3/31 ¤U¤È 03:25:10²Ä 110 ½g¦^À³
|
¦Ñ·à°e¥óADRµo¦æ~~¦Ü¤Ö±N´`¥x·LÅé¼Ò¦¡±NªÑ»ù«O«ù¦b¬Û¹ï°ªÀÉ°Ï,¥H§QADR»ù®æµo¦æ»ù~~ news.cnyes.com/news/id/4078474 ¥H¤W¨Ñ°Ñ¦Ò~~¤Å¥Î¥HªÑ²¼§ë¸ê¶i¥X¨Ì¾Ú |
|
|
·|û¡G³¯¤Ñ®¦10141363 µoªí®É¶¡:2018/3/16 ¤U¤È 05:38:45²Ä 109 ½g¦^À³
|
³o¤@¤ë ¨C¤Ñ¥á³æ¤l ¬å»ù ³Í°òÁ`¤½¥q ½æ¶W 1429 ±i ³o»òÄꪺ6497 ³Í°òÁÙ·íµo¦æ¨é°Ó www.wantgoo.com/stock/astock/agentstat?stockno=6497&type=3.5 ª÷ºÞ·|¤£ºÞ¶Ü ¤S¬O¶BÄF¶Ü¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/3/14 ¤W¤È 12:30:05²Ä 108 ½g¦^À³
|
²Î¤@§ëÅU¬ã¨sû2018²Ä¤@©u¦³Ãö¨È·à±d¦X²z»ùÈ¡A¥¼¨ÓASLAN001Á`±ÂÅvª÷¹w¦ô°Ï¶¡¡A¦X²zÁ`¥«È¦³«D±`¸Ô²Óµû¦ô¡C³o¥÷¬ã¨s³ø§i¼gªº«D±`±M·~¡A¦ý¨Ã¨S¦³§â¦b¤G´ÁÁ{§ÉªºASLAN003«æ©Ê°©Åè©Ê¥Õ¦å¯f¹w¦ô±ÂÅvª÷¦C¤Jµû¦ô¡C ¦Ü©ó¦ó®É·|±ÂÅv¡AÁ`±ÂÅvª÷¬O¦h¤Ö¡A¦b¨S¦³Â½µP«e¡A¨S¦³¤H·|ª¾¹D¡A±ÂÅvªº¤½§i³£¬O¦b¤j®a·N·Q¤£¨ìªº±¡ªp¤Uµo¥Í¡C¥H¤WÓ¤H¤À¨É¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/3/12 ¤W¤È 12:09:33²Ä 107 ½g¦^À³
|
¤¤°êÁx¹DÀù¥«³õ¤£®e©¿µø:¥H¤U¸ê°T¶È¨Ñ°Ñ¦Ò¡C ¨È·à±d¤w¦b¤¤°ê±Ò°Êvarlitinib»Pcapecitabine¦X¨Ö¨Ï¥Îªº¼Ï¯Ã¡B³æÁu¡B¦h¸ÕÅ礤¤ß¤§Á{§É¸ÕÅç¡A¨ü¸Õ¹ï¶H¬°¤w¦Ü¤Ö±µ¨ü¤@½u¥þ¨©ÊªvÀø¤§±ß´Á©ÎÂಾ©ÊÁx¹DÀù¯f±w¡C¦@¦¬68¦ì¨ü¸Õ¡A¥DnÀø®Ä«ü¼Ð¬OORR¡C¹wp±N©ó2018¦~©³³ø§i¸ÕÅç¼Æ¾Ú¡AY¹F¼Ð±N¥i±æ»â¥ý쥻ªº³W¹º®Éµ{¤@¦~¦VCFDA°e¥Xº¦¸²Ä¤G½uÁx¹DÀù·sÃĵù¥Uµn°O¥Ó½Ð¡A¤¤°êÁx¹DÀù¤H¼Æ¹w¦ô14.5¸U¤H¡A¥«³õ¤£®e©¿µø |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/3/9 ¤U¤È 03:09:03²Ä 106 ½g¦^À³
|
°ê¤º²ÎX§ëÅU¤½¥q©ó¤¤¸Î¨ú±oÃÄÃÒ«á,µoªí°ê¤º·sÃIJ£·~µûªR,¦Ó¹w´Á¦Ñ·à±N©ó¤C¤ëµo¦æADR¤ÎALSAN003²Ä¤T©u¦³±æ°ê»Ú±ÂÅv~~ ¥H¤W¨Ñ°Ñ¦Ò.. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/3/7 ¤W¤È 09:07:04²Ä 105 ½g¦^À³
|
©t¨àÃĪºq»ùªGµM¤£¤@¼Ë¡A¨È·à±d¨«¦b¹ïªº¸ô¤W¡AºX¤UGÀùÁx¹DÀù¤wÀò±o¬ü°êFDA©t¨àÃÄ»{©w¨ÃÂùÂù¶i¤J¼Ï§á¸ÕÅç ®¥¶P¤¤¸Î·sÃĤ½¥q,§ë¸ê¤H»P ªø´Á§ë¤J¬ã¨sªº¬ì¾Ç®a»P¬ãµo¤Hû ¤¤¸Î¥ý«e«e¤wÀò±o¬ü°êFDA®Öã³q¹LÀ³¥Î©ó¦h«§ÜÃĩʯf¤H©t¨àÃĸê®æ¡A¨Ã³°ÄòÀò±o¬ð¯}©ÊªvÀø»PÀu¥ý¼f¬d¸ê®æ¡A¥»¤ë6¤éTMB-355Àò±o¬ü°êFDA¥Íª«»s¾¯ÃÄ«~¤W¥«¬dÅçµn°O®Öã¡AÃÄ»ùq¬°¨C¤H¨C¦~¬üª÷11.8¸U¬ü¤¸¡A°ª©ó¥ý«e¥«³õ¹w¦ôªº5¸U¬ü¤¸ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/2/19 ¤W¤È 11:33:07²Ä 104 ½g¦^À³
|
¹Dã¦^Àɤ£¬O¬ü°ê¸gÀÙÂà®z¡A¦Ó¬O«D²z©Êªº³q¿±¾á¼~ ¥xªÑ«ÊÃö¨ì2¤ë16¤é ¬ü°ê¹Dã¤wº¦¶W¹L¤dÂI 24190.90 >>>>> 25219.38 (º¦1028.48ÂI) 6497 ¥~¸ê¶R½æ¤ë³øªí 2018¦~2¤ë ¶R¶W4703±i ½æ¶W1919±i ¶R½æ¶W2784±i (²Îp¨ì 2018¦~2¤ë 12¤é) 2018¦~1¤ë ¶R¶W1281±i ½æ¶W66±i ¶R½æ¶W1215±i 1 ¦Ü 2¤ë12¤é ¶R¶W3999 ±i ¥H¤W¸ê°T¤À¨É¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å°µ¬°§ë¸ê¤§¨Ì¾Ú¡I |
|
|
·|û¡G¤p¦t10145840 µoªí®É¶¡:2018/2/12 ¤U¤È 06:18:44²Ä 103 ½g¦^À³
|
³o¨â¤Ñ¥Dn¬O¬üªL¦b½æ¡A¬üªL¥»¨³£¬O°µµu½u¡Aµu´Á¤º¤£ºÞªÑ»ù¦h¤Ö³£·|½æ¥X¡Aªø½u«ù¦³ªº¤£¥ÎºÞ¥Lªº¾Þ§@¡A¨ä¥L´N¬O«e´X¤Ñ¶Rªº¦³¨Ç¤£·Q³øªÑ¹L¦~ªº½æÀ£¡A¤µ¤ÑÁöµM¥´¨ì¶^°±¦ýÁÙ¬O¦³¤H¦b©Ó±µ |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2018/2/12 ¤U¤È 02:56:36²Ä 102 ½g¦^À³
|
¤£ª¾¬°¦ó³o¨â¤ÑªÑ»ù×¥¿¤£¤Ö¡A¥HÄw½X¨Ó¬Ý¦³¨Ç¬O§«ô¥|°lº¦°±ªº¡AµM«á§«ô¤¦]¬°¬üªÑ¤j¶^±þ¥X¡A¦³¨Ç¥i¯àµu½uÀò§Q¤Fµ²¡A¬Y¨Ç¤jªÑªFÁÙ¬O¤Î«ùÄò½æ¥X¡A¦~«eªº½æÀ£ÁÙ¯uªºÆZ®£©Æ¡AÅý¨È·à±dª½±µ¶^¯}5¤é½u¡A¬Ý¨Ón¾ã²z¤@¬q®É¶¡¤F¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/2/12 ¤W¤È 12:17:19²Ä 101 ½g¦^À³
|
©t¨àÃĤj ¨È·à±d¬O«Ü¦³¼ç¤Oªº§ë¸ê²Õ¦X¼Ðªº¡AASLAN001Áx¹DÀù¡AGÀù¬O©t¨àÃÄ¡AASLAN003¾AÀ³¯g¬OAML«Ü¦³¼ç¤O¡AASLAN004¹L±Ó®ð³ÝÃÄ¥«³õ¤j¡A³o®a¤½¥q·í¤j®a©¿µø¥Lªº¦s¦b®É¤w¸g¦b¤£ª¾¤£Ä±¤¤³Q¥~¸ê¬Ý¤¤¡A¤j®a¤@°_¥[ªo¡C¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú¡C |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2018/2/9 ¤W¤È 11:07:47²Ä 100 ½g¦^À³
|
Ãĵؽ¬õ¤jº¦¤F ©Î³\éw·àµ¥¤@¤U¤]¦³¾÷·| ¦b³oÓ¸`°©²´¡An¹³ÃĵؤΨȷà³oºØ¦³§Y´Á«¤j§Q¦hªÌ¤~·|¨ü·ú·ý |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/2/9 ¤W¤È 10:36:45²Ä 99 ½g¦^À³
|
¥xÁÞ¤j, ¤]·PÁ§A±`±`¤À¨É«D±`¦³¥Îªº°T®§~~¤½¥q¸Ó°µªº³£°µ¤F,±µ¤U¨Ó´N¬OÁ{§É¼Æ¾Ú,ADRq»ù¤Îµo¦æ®ÉÂIªº°ÝÃD¤F~~Y¥H¬ü°ê´îµ|¤Î¶Å¥«¶]¥X¨Óªº¸êª÷¨Ó¬Ý, ¦³¼ç¤Oªº·à¤lÀ³¸Ó«Ü¦³¾÷·|³Q«C·ý... ¥H¤W¨Ñ°Ñ¦Ò~~ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/2/8 ¤U¤È 11:01:16²Ä 98 ½g¦^À³
|
¦Ñ´¤j ·à¤Í³£«Ü·PÁ¦Ѵ¤jµL¨p´£¨ÑÂå¾Ç±M·~¤À¨É,¥u¯à¥Î¹d²ÓÃû¿ò¨Ó§Î®e. ¬Û«H¦³¥»½èªº¥Í§Þ¤½¥q³£·|¦³ªí²{ªº¾÷·|,¢±¢¯¢°¢·¡@¥xÆW¥Í§Þ¥[ªo¡@¤j®a¥[ªo¡I¡@ª¯¨Ó´I¡@¡I¡@¡@ ¡@¡@ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/2/8 ¤U¤È 10:38:36²Ä 97 ½g¦^À³
|
¦Û±q·à¤l2018¦~1¤ë10¤é¨ì¬ü°êª÷¤s°Ñ©ó¼¯®Ú¤j³qÁ|¿ì¤§²Ä36©¡ÂåÀø«O°·¦~·|µoªí¤½¥q²³ø«á¥~¸ê¶R¶W±¡ªp 2018¦~ 1¤ë ¶R¶W 1215 ±i 2018¦~ 2¤ë ¶R¶W 3153 ±i ( ²Îp¨ì2¤ë8¤é¤î ) 1¤ë+ 2¤ë1¤é-2¤ë8¤é Á`¦@¶R¶W4368 ±i ¶R¶Wì¦]¤£©ú?¡@¡]Äw½X¶V§l¶V°®²b¡I¡^ ·s¥[©Y¨Ó¥x±¾µPªº¥Í§Þ¤½¥q6497°÷®ð¾z , ª½±µ¨ì¬ü°êµo¦æADR ¤£¸ò§ë¸ê¤H®³¿úÁÙ°eµ¹ªÑªF¤j¬õ¥]¡I¡@ ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò,½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2018/2/8 ¤U¤È 09:23:28²Ä 96 ½g¦^À³
|
¨È·à±d-KY(6497)±NµoADR¡A¥~¸ê¥ý¥d¦ì¡AGÀù·sÃĪì¨B¼Æ¾Ú¤µ¦~´¦¾å ¡i°]°T§Ö³ø¡þ¦ó¬ü¦p³ø¾É¡j¨È·à±d-KY(6497)¶}µo¤¤·sÃÄvarlitinib©óÁx¹DÀù¡BGÀù¡B¨ÅÀù»P¤j¸zª½¸zÀù¤§Á{§É¼Æ¾Ú¥¿±¡A¥«³õ´Á«Ý¥Î©óªvÀø±ß´Á©ÎÂಾ©ÊGÀù¤§¥þ²y¤G/¤T´Á¸ÕÅç¡Aªì¨B¼Æ¾Ú¹wp2018¦~´¦ÅS¡A¤½¥q¤é«e¤w¤j¤âµ§¶R¦^¥þ²y°Ó«~¤ÆÅv§Q¡A¨Ã³W¹º¤µ¦~¦b¬ü°êµo¦æADR(¬ü°ê¦s°U¾ÌÃÒ)¡A¥«³õ°¾¦h¬Ý«Ý¡A¥~¸ê¤]¿n·¥¥d¦ì¡Aµuµu7Ó¥æ©ö¤é¤w¶R¶W2400±i¡A¿EÀyªÑ»ù½Ä¤W53.5¤¸³Ð8Ó¤ë·s°ª¡C ¨È·à±d¾Ö¦³¤¶µÔ¿ïÃĪ«¤Î¤@ÓModybodies¥¥x¡A¥DnÃĪ«varlitinib (ASLAN001)¬ãµo¤¤¤§¾AÀ³¯g¥]¬AÁx¹DÀù¡BGÀù¡BÂಾ©Ê¨ÅÀù»PÂಾ©Ê¤j¸zª½¸zÀù¡CVarlitinib¤é«e¤w¨ú±o¬ü°êFDA®Öã®i¶}Áx¹DÀù¥þ²y¤G´Á/¤T´Á¼Ï¯ÃÁ{§É¸ÕÅç¡A¹wp¥¼¨Ó2-3¦~§¹¦¨¡C ¦Ó¥~¬ÉÃöª`ªºvarlitinib©ó²Ä¤@½u(HER1/ HER2¦@¦Pªí²{)±ß´Á©ÎÂಾ©ÊGÀù¤§¥þ²y¤G/¤T´Á¸ÕÅç¡A¥h¦~¤w¶}©l¦¬®×¡A¦Xp±N©Û¦¬¬ù40¦ìHER1/ HER2¦@¦Pªí²{¥B¥ý«e¥¼±µ¨ü¹L¥þ¨©ÊªvÀøªº¯f±w¡Aªì¨B¼Æ¾Ú¹wp2018¦~´¦ÅS¡A¤T´ÁÁ{§É«h¹wp©ó¥¼¨Ó4-5¦~§¹¦¨¡CGÀù¬O¨È¬w²Ä¤G¤jÀù¡A¬ü¤¤¤éÁú¨C¦~¦º¤`¼Æ64.5¸U¤H¡A¥«³õ¹ï¥¼¨Óµo®i±H¤©«p±æ¡C varlitinib©óÂಾ©Ê¨ÅÀù¤§¾AÀ³¯g¶i«×¬°¤w§¹¦¨²Ä2a´ÁÁ{§É¸ÕÅç¡A¸Ó¸ÕÅçÂê©wHerceptinªvÀø¥¢±ÑªºHER2ÂX¼W¯f±w¡A´Á¤¤¤ÀªR¸ê®ÆÅã¥Ü¡Avarlitinib¹ï¯f±w²£¥Í·¥¨Î¤§Àø®Ä¡A¥B@¨ü©Ê¤Î¦w¥þ©Ê¨}¦n¡C ¬°´x´¤¦Û¦æ±NÃĪ«±a¤J¥«³õ¨Ã¦b¯S©w¦a°Ï°Ó«~¤ÆÅv§Q¡A¨È·à±d¤é«e¤w«Å¥¬¡A±qArray BioPharma¨ú±o¥þ²y¶}µo¡B»s³y»P°Ó«~¤Ævarlitinib¤§©Ò¦³Åv¡Añ¬ùª÷»P¨½µ{¦Xp¤£¶W¹L1.29»õ¬ü¤¸¡A¥¼¨Ó¾P°âÅv§Qª÷¤£¶W¹L§CÂù¦ì¼Æ¡C ¨È·à±d¤é«e«Å¥¬¡A±N¦b¬ü°êµo¦æADR¡Aªñ¤é¤w¨ú±oª÷¿ÄºÊ·þºÞ²z©eû·|ª÷ºÞÃÒµo¦r²Ä1060049975¸¹®Öã¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ¡A¹wp¶Ò¸ê4852¸U¬ü¤¸¡A§é¦X·s¥x¹ô¬Ò¬ù14»õ¤¸¡A¥~¬É¹w´Á¡A¤µ¦~´N·|µo¦æ¡A¨Ã¦³§U»P°ê»Ú±µy¡C |
|
|
·|û¡GLin10142144 µoªí®É¶¡:2018/2/8 ¤U¤È 04:18:57²Ä 95 ½g¦^À³
|
n³Q¨ÖÁʤF¶Ü¡H |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2018/2/7 ¤W¤È 09:20:46²Ä 94 ½g¦^À³
|
²ö«D¯u¬Oéw·à? |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2018/2/7 ¤W¤È 08:26:30²Ä 93 ½g¦^À³
|
¥~¸ê¬Q¤Ñ³{§C¤S±½¤F500¦h±i ·s»D»¡¤½¥q¤µ¦~nu¬üµo¦æADR ªüÁø»¡¦³¤@ÀɧC»ù¥Í§ÞªÑnº¦¤@¿¬Oéw·à¶Ü? |
|
|
·|û¡GLin10142144 µoªí®É¶¡:2018/2/1 ¤U¤È 03:36:42²Ä 92 ½g¦^À³
|
ÁÞ®vÁÂÁ±z¡D¥[ªo |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/2/1 ¤W¤È 08:42:15²Ä 91 ½g¦^À³
|
Lin ¤j ¨È·à±d¤½¥qºô¯¸³Ì·s®ø®§¡G¡@¨È·à±d±NÃÙ§U 2018 ¦~ÁxºÞÀù°òª÷·|¦~·| aslanpharma.com/zh/2018/01/31/aslan-pharmaceuticals-sponsors-cholangiocarcinoma-foundation-annual-conference-2018/ ¨È·à±d±NÃÙ§U 2018 ¦~ÁxºÞÀù°òª÷·|¦~·| 2018 ¦~ 1 ¤ë 31 ¤é¡A·s¥[©Y¡V±Mª`©ó¶}µo¨È¬w²±¦æ»P¼Ú¬ü©t¨à¯e¯fÀù¯g¡B¦ì©óÁ{§É¶¥¬q¤§¥Íª«»sÃĤ½ ¥q¨È·à±d-KY (6497)¤µ¤é«Å¥¬±N¾á¥ô 2018 ¦~ÁxºÞÀù°òª÷·|¦~·|¤§¾ó¾ð¯ÅÃÙ§U°Ó(Oak sponsor)¡A¦¹·|ij ±N©ó¬ü°êµS¥L¦{ÆQ´ò«°Á|¦æ¡C ¥ÑÁxºÞÀù°òª÷·|Äw¿ì¤§¦~·|±N©ó 2018 ¦~ 1 ¤ë 31 ¤é¦Ü 2 ¤ë 2 ¤éÁ|¦æ¡AÁܽЬã¨s¤Hû¡BÂåÀø«O°·±M·~ ¤H¤h¡B¬Fµ¦¨î©wªÌ¡B¯f±w¤Î·ÓÅ@ªÌ»ô»E¤@°ó¡A³z¹L¦¹¦¸ª¾ÃÑ»P³Ð·s¥æ¬y¤§½×¾Â¡A«P¶iÂå¬É»P¾Ç¬É±´ ¨sÁxºÞÀù¬ÛÃöijÃD¡C ¨È·à±d-KY ±N¦b¥»¦¸·|ij¤¤°w¹ï TreeTopp ¸ÕÅç³]p(Treatment Opportunty)µoªí²³ø¡CTreeTopp ¬°¤@ ¶µ¥¿¦b¶i¦æ¤¤¤§¥þ²y¼Ï¯ÃÁ{§É¸ÕÅç¡A¥Øªº¬°±´°Q¨È·à±d-KY ¥DnÔ¿ïÃĪ« varlitinib ©óÁx¹DÀù¤§Àø ®Ä¡C¥»¦¸Â²³ø±N¤£·|µoªí·sªº¬ã¨s¼Æ¾Ú¡CVarlitinib ¤wÀò±o¬ü°ê¹«~ÃĪ«ºÞ²z§½(US FDA)Áx¹DÀù¨È«¬¢w ÁxºÞÀù¤§©t¨àÃĸê®æ»{©w¡C ¨È·à±d-KY Âå¾Çªø Bertil Lindmark ³Õ¤hªí¥Ü¡G¡uų©ó¥Ø«e¦bÁxºÞÀù»P¨ä¥L§Î¦¡¤§Áx¹DÀù©|µL®Ö㤧Àø ªk¡A³oÃþ¯e¯f¢¤Á»Ýn¦³®ÄÀøªkªº¬ãµo¥H¦]À³¥þ²y¤§ÂåÀø»Ý¨D¡C¨È·à±d-KY «Üºa©¯¯à°Ñ»P¤ä«ù³o¶µ« nªº·|ij¡AÅýÂåÀø¬ÉÂǦ¹¾÷·|¯à°÷°w¹ï¯f±w¤ä«ù·ÓÅ@¡B¯e¯f»{ª¾«Ø¥ß¤Î·sªvÀø¿ï¾Üµo®iµ¥±¦V¶i¦æ ¥æ¬y¡C¡v Ó¤H¤À¨É ¢°³Ìªñ¥~¸êªº½T¤@ª½¶Rì¦]¤£©ú? ³o¤w¤Þ°_¤j®aª`·N!¨È·à±dªº¥~¸êªø´Á§ë¸ê©~¦h,¤£¥²²z·|§ëÅUµu´Á¾Þ§@ ¢±¨È·à±d±NÃÙ§U 2018 ¦~ÁxºÞÀù°òª÷·|¦~·|¥Øªº¬O§i¶D¬ü°ê¯f±wVarlitinib¥þ²y¼Ï¯ÃÁ{§É³]p,§ÜÀù¾÷¨î, (US FDA)Áx¹DÀù©t¨àÃĸê®æ»{©w¡C¥Ø´ÁªvÀøª¬ªp, ·¾³q»¡©ú¥H¤è«K¯f±w©Û¶Ò¨Ã¬°¥¼¨ÓÃĪ«¤W¥«¥´ª¾¦W«×¡^ ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò,½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú |
|
|
·|û¡GLin10142144 µoªí®É¶¡:2018/1/31 ¤U¤È 11:27:36²Ä 90 ½g¦^À³
|
ÁÞ®v¡G¤µ¤Ñ±çºÑÁøªüÀ¨¡D¥s¤H§â·à¤l¥þ±þ¥ú¤F¡A ©_©Ç¥~¸ê¤@ª½¥[½X¡D§ÖÅܦ¨¥~¸ê¤½¥q¤F |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/1/30 ¤U¤È 10:06:53²Ä 89 ½g¦^À³
|
³oӨȷà±d©xºô¤½§iªº¸ê°T¤ñ¸û§¹¾ã 2018¦~1¤ë8¤é¡A·s¥[©Y ¡V±Mª`©ó¶}µo¨È¬w²±¦æ»P¼Ú¬ü©t¨à¯e¯fÀù¯g¡B¦ì©óÁ{§É¶¥¬q¤§¥Íª«»sÃĤ½¥q¨È·à±d-KY (6497)¤µ¤é«Å¥¬¡A¦bªñ´Á»PCFDA(¤¤°ê°ê®a¹«~ÃĪ«ºÞ²zÁ`§½)§¹¦¨varlitinibÁx¹DÀùÁ{§É¸ÕÅçµo®iµ¦²¤¤§°Q½×«á¡AY¸g®Öã¡Avarlitinib¦b¤¤°ê°Ó«~¤Æ¤§¶i«×±N¥i±æ¸û¹w´Á´£¦¤@¦~¡C ¨È·à±d-KY°õ¦æªø³Å«i³Õ¤hªí¥Ü¡G¡u¤¤°êªñ´Áªk³Wªº§ïÅÜ¥Nªí¤F°w¹ï¦pÁx¹DÀùµ¥¥¼³Qº¡¨¬¥«³õªº·sÃĵo®i±N¥i±æ¥[³t¡A³o±N¨Ï¨È·à±d-KY¦³¾÷·|¥i¥H§ó§Ö¦a¬°¶È¦³¤Ö¼ÆªvÀø¿ï¾Ü¤§¯f±w±a¨Ó·s¿o¥B«nªºªvÀø¿ï¶µ¡C¨È·à±d-KY¤w©óªñ´Á¨ú±ovarlitinib¥þ²y¶}µo»P°Ó«~¤Æ¤§©Ò¦³Åv¡A§Ú̲{¥¿µÛ¤â¥´³y¦b¤¤°êªº¹Î¶¤¡A¬°varlitinibªº¤W¥«°µ·Ç³Æ¡C¡v ¨È·à±d-KY¤w©ó2017¦~¦b¤¤°ê±Ò°Êvarlitinib»Pcapecitabine¦X¨Ö¨Ï¥Îªº¼Ï¯Ã¡B³æÁu¡B¦h¸ÕÅ礤¤ß¤§Á{§É¸ÕÅç¡A¨ü¸Õ¹ï¶H¬°¤w¦Ü¤Ö±µ¨ü¤@½u¥þ¨©ÊªvÀø¤§±ß´Á©ÎÂಾ©ÊÁx¹DÀù¯f±w¡C¦¹¸ÕÅç¥Ñ¾á¥ô¤¤°êÁ{§É¸~½FÂå¾Ç·|¥D®u¡B¸Ñ©ñx«n¨Ê¤K¤@Âå°|°Æ°|ªøªº¯³¨û¶f±Ð±Â¥D¾É¡C ¸Ó¸ÕÅç±Nµû¦ô¦@68¦ì¨ü¸Õ¯f±w¦bvarlitinib»Pcapecitabine¦X¨Ö¨Ï¥Îªº¦w¥þ©Ê»P@¨ü©Ê¡A²{¤w±Ò°Ê¨ü¸Õ¯f±w©Û¦¬§@·~¡A¨ä¥Dn¸ÕÅç¥Ø¼Ð¬°«ÈÆ[¤ÏÀ³²v(ORR)¡C¨È·à±d-KY¹wp±N©ó2018¦~©³³ø§i¸ÕÅç¼Æ¾Ú(top-line data)¡AY¥Dn¸ÕÅç¥Ø¼Ð¹F¨ì¹w´Á¡A±N¥i±æ»â¥ý쥻ªº³W¹º®Éµ{¡A´£¦¦VCFDA°e¥Xº¦¸²Ä¤G½uÁx¹DÀù·sÃĵù¥Uµn°O¤§¥Ó½Ð¡C ¨È·à±d-KY¤w»P¤¤°ê¤§¥Í²£¹Ù¦ñ±K¤Á¦X§@¡AÂù¤è¤w¦b¤µ¦~ªì¨î©w²Å¦XGMP¼Ð·Ç¤§¥Í²£¬yµ{¡C¤½¥q¹w´Ávarlitinib¤§¥Í²£¨ÑÀ³Ãì±N¦b2018¡B2019¦~´N¦ì¡A¥H¤äÀ³·sÃĵù¥Uµn°O»P¤§«á¤§¤W¥«»Ý¨D¡C ¨Æ¹ê¤W¡A¨C¦~¦b¨È¬w·s¼W¤§Áx¹DÀù¯f¨Ò¬ù¦³20¸U¨Ò¡A¨ä¤¤¤¤°ê´N¦û¤F14.5¸U¡F¦Ó¦b³Qµø¬°¬O©t¨à¾AÀ³¯gªº¬ü°ê¡A¨C¦~«h¬ù¦³1.26¸U¤§·s¼WÁx¹DÀù¯f¨Ò¡C¥Ø«eÁx¹DÀù¦b¤¤°ê»P¬ü°ê¬Ò©|µL³Q®Ö㤧Àøªk¡C Ó¤H¤À¨É: 1¨C¦~¦b¨È¬w·s¼W¤§Áx¹DÀù¯f¨Ò¬ù¦³20¸U¨Ò¡A¨ä¤¤¤¤°ê´N¦û¤F14.5¸U ¥«³õ¤£®e¤p觑 2±À¦ô¤¤°êÁx¹DÀù¤W¥«®É¶¡¬ù¦b2020¦~ 3±À¦ô¤¤°ê»P¬ü°ê¤W¥«®É¶¡«D±`±µªñ ¥H¤WÓ¤H¤À¨É±À´ú¬O¨Ì¾ÚA B A ¥h¦~12¤ë®ü¥~ªk»¡·|²³ø, 2019 ¦~ Varlitinib¦b¦U¤j¥Dn¥«³õ´£¥XÁx¹DÀùÃÄÃҥӽРB 2018¦~1¤ë8¤é©xºô³Ì·s®ø®§: ¤½¥q¹w´Ávarlitinib¤§¥Í²£¨ÑÀ³Ãì±N¦b2018¡B2019¦~´N¦ì »P¤¤°êÁx¹DÀù¤H¼Æ ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò,½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/1/18 ¤W¤È 09:50:12²Ä 88 ½g¦^À³
|
¤ñ¸û°ê¤º³\¦h·sÃĤ½¥q¨È·à±d¨úÃÒªº®Éµ{¹w¦ô¦¤F³\¦h,¦b³oÃÄ¿z¥¥x¶V¨Ó¶V¼F®`ªº¤j¼Æ¾Ú®É¥N,¥ý°w¹ï©t¨àÃĽdÃ¥ºÉ³t®³¨ìÃÄÃÒ¤~¬O¨È¬w·sÃĤ½¥qªº§Q°ò~~~ 1.¨È·à±d¤j³°ÁxºÞÀùªº¶µ¥Ø~~¦³±æ´£¦¤@¦~,³sµ²¦p¤U: www.chinatimes.com/realtimenews/20180108003886-260410 2.³Ì·sªk»¡·|¸ê®Æ(»P¥ý«e¬Û¦P,¶È¦³°Ï°ì±ÂÅv®×©Ôªø¦Ü¥þ¦~¹ê²{) ¥H¤W¨Ñ°Ñ¦Ò, §ë¸ê¦Ût¬ÕÁ«~~ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/1/8 ¤U¤È 04:20:03²Ä 87 ½g¦^À³
|
¨È·à±d¤j³°ÁxºÞÀùªº¶µ¥Ø~~¦³±æ´£¦¤@¦~,³sµ²¦p¤U: www.chinatimes.com/realtimenews/20180108003886-260410 ¥H¤W¨Ñ°Ñ¦Ò, §ë¸ê¦Ût¬ÕÁ«~~ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2018/1/4 ¤W¤È 08:44:46²Ä 86 ½g¦^À³
|
¸òarray½Í¦n±ÂÅv¤Î¨½µ{«á,´N¯àµL«áÅUªº¥h½Í¤U´å¾P°â±ÂÅv¤F~~~´Nµ¥¤U´å±ÂÅv¤Î´Á¤¤¼Æ¾Ú¤F~~¥[ªo¦Ñ·à |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2017/12/14 ¤U¤È 07:49:10²Ä 85 ½g¦^À³
|
¥ÃÂת÷«n¨Ê¤µ¤é«ùÄò˳f ¦ý¥«³õ¤]¦³¤H¤£Â_§C±µ ÁÙ¦n°Õ!³{§CºCºC±µ¡A¨Ó¤ñ½Ö®ðªø |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2017/12/13 ¤U¤È 04:09:39²Ä 84 ½g¦^À³
|
ÁöµM³Í°òÁ`¤½¥q¨S¦b½æªÑ¡A¤£¹L¤µ¤Ñ¤S¶]¤@®a¥ÃÂת÷«n¨ÊˤF176±i¥X¨Ó¡AªÑ»ùª½±µ¤U±þ¨ì32¡A¤£ª¾¤½¥q¬£¯à®³¥X¤°»ò¤èªkÅýªÑ»ù¤î¶^©O? µo¦æADR¸ò®ü¥~±ÂÅv³£ÁÙ¨S¨º»ò§Ö¥i¥H¦³µ²ªG¡A¦ý¬OªÑ»ù¦b¨SÔ£§QªÅ¤§¤U¤@¸ô©¹¤U±´¡A¤£ª¾¹D¦ó®É¤~¯à¤î¶^¦^¤É©O? |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2017/12/13 ¤U¤È 01:32:06²Ä 83 ½g¦^À³
|
§Úı±o¤½¥q¦A¤£¥X¨Ó¹ïªÑ»ù°µ¤@ÂI±¹¬I¡A§ë¸ê¤H¦±ß·|¨S«H¤ßªº! |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2017/12/12 ¤U¤È 07:51:39²Ä 82 ½g¦^À³
|
¤µ¤Ñ³Í°òÁ`¤½¥q²×©ó°±½æ¤F¡A¦n²{¶H |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/12/12 ¤W¤È 08:07:03²Ä 81 ½g¦^À³
|
²×©ó¦³¾÷·|³Q¥@¬É¬Ý¨£ªº¨º¹D¥ú¤F~~¬ü°ê¤j´T´îµ|¦b§Y¹w´Á¦³¸êª÷¦^¬y¬ü°ê,§ë¸ê»ùȦ³¾÷·|³Q¬Ý¨£~~~ ¥[ªo |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2017/12/12 ¤W¤È 12:14:49²Ä 80 ½g¦^À³
|
¤£¬O¸òìªÑªF²{ª÷¼W¸ê¡A¤ÓÆg¤F Åý§ó¦h¤H¬Ý¨£¨È·à±d§a |
|
|
·|û¡G¤p¦t10145840 µoªí®É¶¡:2017/12/11 ¤U¤È 11:21:27²Ä 79 ½g¦^À³
|
µo¦æadr³o¼Ë¤]¦nªü °ê¥~Ävª§§ó¿E¯P ¯à¦³°ªªÑ»ùªí¥Ü¦³¯u¥»¨Æ ¥xÆW§ë¸ê¤H¤~¯à§ó¦w¤ß |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2017/12/11 ¤U¤È 11:18:09²Ä 78 ½g¦^À³
|
³o¸ê°T¤Ó´Î¤F¡I¹ï¨È·à±dªº§Þ³N´£¤É¡A±j¤Æ°ê»ÚÄvª§¤O¡A´£¤É¾ãÅé¬ãµo¯à¶q¡A§ïµ½°]°Èµ²ºc¡A´£¤É¨ÖÁʯà¤Oµ¥§U¯q «Ü¤j¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2017/12/11 ¤U¤È 09:36:07²Ä 77 ½g¦^À³
|
§Æ±æµo¦æADR¤§«á¨ü¨ì°ê¥~§ë¸ê¤HªÖ©w¡AªÑ»ù¦A±q°ê¥~º¦¦^¥xÆW¡I «¢«¢«¢¡I |
|
|
·|û¡GMBE10145047 µoªí®É¶¡:2017/12/11 ¤U¤È 09:17:52²Ä 76 ½g¦^À³
|
½T¦p³¡¤À§ë¸ê¤H©Ò´Á¬ß,¨È·à±d¸³¨Æ·|¤µ¨Mij²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æADR 1.¸³¨Æ·|¨Mij¤é´Á:106/12/11 2.¦WºÙ¡£XX¤½¥q²ÄX¦¸¡]¦³¡BµL¡^¾á«O¤½¥q¶Å¡¤:²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U ¾ÌÃÒ¡C 3.µo¦æÁ`ÃB:¨Ì¬ü°ê¦s°U¾ÌÃÒ¹ê»Úµo¦æ³æ¦ì¼Æ¤Î¨ä»ù®æq¤§¡C 4.¨C±i±ÃB:·s¥x¹ô10¤¸ 5.µo¦æ»ù®æ:¹ê»Úµo¦æ»ù®æ¨Ì¤¤µØ¥Á°êÃÒ¨é°Ó·~¦P·~¤½·|©Ó¾P°Ó·|û»²¾Éµo¦æ¤½¥q¶Ò¶° »Pµo¦æ¦³»ùÃÒ¨é¦Û«ß³W«h¡]¤UºÙ¡u¦Û«ß³W«h¡v¡^³W©w¡A¤£±o§C©óq»ù¤é´¶³qªÑ¦¬½L»ù ¡A©Îq»ù¤é«e¤@¡B¤T¡B¤ÓÀç·~¤é¾Ü¤@pºâ¤§´¶³qªÑ¦¬½L»ù¤§Â²³æºâ³N¥§¡¼Æ¦©°£µL Àv°tªÑ°£Åv¡]©Î´î¸ê°£Åv¡^¤Î°£®§«á¥§¡ªÑ»ù¤§¤E¦¨¡C±©¹ê»Úµo¦æ»ù®æ±ÂÅv¸³¨Æªø©ó «ez½d³ò¤º¡A¨Ì°ê»ÚºD¨Ò¨Ã°Ñ¦Ò¸ê¥»¥«³õ¤Î·JÁ`°éÁʱ¡§Îµ¥¡A¬¢ÃÒ¨é©Ó¾P°Ó¦@¦Pij©w ¤§¡C 6.µo¦æ´Á¶¡:¤£¾A¥Î¡C 7.µo¦æ§Q²v:¤£¾A¥Î¡C 8.¾á«O«~¤§Á`Ãþ¡B¦WºÙ¡Bª÷ÃB¤Î¬ù©w¨Æ¶µ:¤£¾A¥Î¡C 9.¶Ò±o»ù´Ú¤§¥Î³~¤Î¹B¥Îpµe:½Õ¾ã±ÂÅv¥æ©ö¬[ºc¡B¶i¦æ¬ãµo»s³y¬¡°Ê¡BÁʶR±M§Q¡B«Ø¥ß °Ó·~¼Ò¦¡¥H´£¤ÉªÑªF§Q¯q¡C 10.©Ó¾P¤è¦¡:¨Ì106¦~²Ä¤@¦¸ªÑªFÁ{®É·|¤§¨Mij¡A°£«O¯d¤©¥»¤½¥qû¤u»{Áʤ§ªÑ¥÷¥~¡A¨ä ¾l90%¤§·sªÑÁ`¼Æ¥þ³¡¥R§@µo¦æ®ü¥~¦s°U¾ÌÃÒ¤§ì¦³»ùÃÒ¨é¡C 11.¤½¥q¶Å¨ü°U¤H:¤£¾A¥Î¡C 12.©Ó¾P©Î¥N¾P¾÷ºc:¥¼©w¡C 13.µo¦æ«OÃÒ¤H:¤£¾A¥Î¡C 14.¥N²zÁÙ¥»¥I®§¾÷ºc:¤£¾A¥Î¡C 15.ñÃÒ¾÷ºc:¤£¾A¥Î¡C 16.¯àÂà´«ªÑ¥÷ªÌ¡A¨äÂà´«»ù®æ¤ÎÂà´«¿ìªk:¤£¾A¥Î¡C 17.½æ¦^±ø¥ó:¤£¾A¥Î¡C 18.¶R¦^±ø¥ó:¤£¾A¥Î¡C 19.ªþ¦³Âà´«¡B¥æ´«©Î»{ªÑªÌ¡A¨ä´«ªÑ°ò·Ç¤é:¤£¾A¥Î¡C 20.ªþ¦³Âà´«¡B¥æ´«©Î»{ªÑªÌ¡A¹ïªÑÅv¥i¯àµ}ÄÀ±¡§Î:¤£¾A¥Î¡C 21.¨ä¥LÀ³±Ô©ú¨Æ¶µ:¥»¦¸¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»P¬ü°ê¦s°U¾ÌÃҮסA«Y¸g106¦~10¤ë 20¤é¸³¨Æ·|¤Î106¦~12¤ë8¤éªÑªFÁ{®É·|¨Mij³q¹L¡AÀÀ¥H²{ª÷¼W¸êµo¦æ´¶³qªÑ 30,000,000ªÑ¦Ü45,000,000ªÑ½d³ò¤º°Ñ»Pµo¦æ¤§¡A¨Ã±ÂÅv¸³¨Æªø©ó¸Ó½d³ò¤ºµø¸ê¥»¥«¡@ ³õ±¡ªp½Õ¾ã¹ê»Úµo¦æªÑ¼Æ¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2017/12/10 ¤W¤È 11:23:26²Ä 75 ½g¦^À³
|
¸³¨Æ·|¤U§«ô´N·|¥l¶}¤F¡A©¡®É´N·|¨M©w¶Ò¸ê¤è¦¡¤F¡A¤j®a¬Ý¨Ó³£·Pı¥Ø«e¥xÆW¹ï¥Í§ÞªÑ³£¤£¬Ý¦n°Ú¡A¤£¹L¤]¬O¥Ñ©ó¥Ø«e¨È·à±d¤]ÁÙ¨S¦³¹ê½èªºµo®i¡A¹³®ü¥~±ÂÅv¸òÃÄÃÒ¤]³£ÁÙ¨S®³¨ì¡AnÅý§ë¸ê¤H¶R±b¤]¤£®e©ö¡A¥[¤W¤§«eªÑªF³Í°ò²{¦b¤Ñ¤Ñ½æ¡AªÑ»ùµu®É¶¡n¤Wº¦¥i¯àÁÙn¤@¬q®É¶¡µ¥Äw½X¨H¾ý¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2017/12/9 ¤U¤È 09:20:41²Ä 74 ½g¦^À³
|
¤p¦t¤j Á{®ÉªÑªF·|¥u°Q½×Äw¸ê®× ¨Mij´N¬O¨º¥÷²³æªº·s»D½Zªü Äw¸ê®×¤w³q¹L¡A¦Ü©óÄw¸ê¤è¦¡«Ý¸³¨Æ·|¶}·|¨M©w |
|
|
·|û¡GMBE10145047 µoªí®É¶¡:2017/12/9 ¤U¤È 08:35:48²Ä 73 ½g¦^À³
|
IPOªº¥Øªº,°£¤F¤½¥q§V¤O³Ð³yÅý¥«³õ»{¦Pªº»ùÈ,ªÑªF¯à¨É¨üªÑ»ù¤Wº¦ªº³ø¹S¤§¥~ §ó§Æ±æÂǥѪÑÅv¾A«×ªº¤À´²,¦bÀç¹B»Ýn®É¯à¶¶§Q±q¥«³õÄw±¹¸êª÷; Y¬OªÑ»ù«ùÄò¤U¶^,¤½¥q»{¬°¸gÀç»ùÈ¥¼¦X²z¤ÏÀ³(·íµM³o¬O¤½¥q¤ù±Æ[ÂI) ´X¥G²¿®§ªº§C¦¨¥æ¶qÅýªÑÅvµLªk¦³®Ä¤À´²,±N¨ÓnÄw¸ê®É¤S´X¥G¬O¦Vì©lªÑªFÄw´Ú ¨º¦ó¥²IPO©O? ¦ÛµM¤½¥q·|¦³Â੹¨ä¥L¥«³õªº·Qªk §Æ±æ¤£n¨«¨ì³o¤@¨B¤F |
|
|
·|û¡G¤p¦t10145840 µoªí®É¶¡:2017/12/9 ¤U¤È 08:20:49²Ä 72 ½g¦^À³
|
12/8¤£¬O¦³¶}Á{®ÉªÑªF·| ¨ì²{¦b³£ÁÙ¨S¦³®ø®§ªü ¥u¦³¬Ý¨ì¤@ӫܲ³æªº·s»D½Z |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2017/12/9 ¤U¤È 06:09:59²Ä 71 ½g¦^À³
|
¦pªG±q¥x¤U¥«Âà¥h°ê¥~¤W¥« §ë¸êªÌ¥²¶·±j¨î½æ¥XªÑ²¼ ³o¼ËÁÙÆZ¨S«O»Ùªº ´Nºâ¬O¨â®Ú°±ªO·¸»ù¶R¦^¤]©ó¨ÆµL¸É ¦]¬°«Ü¦h¤H¬O¶R¦b40´X¬Æ¦Ü68ªº §Æ±æ·à¤l³Ì«á¤£·|¨«¨ì³o¨B¡A¥[ªo |
|
|
·|û¡G¤p¦t10145840 µoªí®É¶¡:2017/12/8 ¤U¤È 10:36:22²Ä 70 ½g¦^À³
|
Ó¤Hı±o¤£¬O¥xÆW§ë¸ê¤H¤£¶R³æ,¦¨ÁZÁÙ¨S°µ¥X¨Ó·à¤l²{¦b³oÓ»ù¨S¸Ü¦n»¡,¤S¦³¤j¤á¤Ñ¤Ñ½æªÑ²¼ ±ÂÅvª÷®³¨ì/ÃÄÃÒ®³¨ì,ªÑ»ù¤£öt¤]Ãø,¤j®a¤]¤£³ßÅw¤@°ï¥Í§ÞªÑ¨S¦¨ÁZ´N¤T¦ì¼Æ¤£¬O¶Ü ´Nºâ¬ü°ê±¾µP«Ü¦h¤½¥qªÑ»ù¤Í¬O±q1¬ü¤¸¶}©lªº ·à¤l¥[ªo |
|
|
·|û¡Gkenken10138351 µoªí®É¶¡:2017/12/8 ¤U¤È 10:21:19²Ä 69 ½g¦^À³
|
¤U¿³Âd¨S¦³¥ô¦ó¼vÅT¡AªÑ²¼ÁÙ¬O¥i¥H¥æ©ö¡A¦b¥¼¤W¥«½L°ÓÁÙ·|¦³¥æ©ö ¤§«eªF´Ë¹qµø¤]¬O¤U¿³Âd¡A²{¦b¥¼¤W¥«½L¤]¦³»ù®æ |
|
|
·|û¡GMBE10145047 µoªí®É¶¡:2017/12/8 ¤U¤È 08:42:22²Ä 68 ½g¦^À³
|
¦L¶H¤¤F*AS¬O·¸»ù¤@®Ú¦h°±ªO¶R¦^ ³o¦¸°·¥ÃºM¿³ÂdÀ³¸Ó¤]¬Oij»ù¶R¦^¦b¥~¬y³qªÑÅv ¦p¦³¿ù»~,½Ð¨ä¥L¥ý¶i«ü¥¿/¸É¥R |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2017/12/8 ¤U¤È 07:25:09²Ä 67 ½g¦^À³
|
½Ð±Ð·à¤Í °²³]¤½¥q¨M©w±q¥x¤U¥«¨ì¨ä¥L°ê®a¤W¥« ¨º¹ï§Ú̲{¦³§ë¸ê¤H·|¦³¤°»ò¼vÅT? ·|³Q±j¨î²{»ù½æ¥Xµ¹¤½¥q¶Ü?ÁÙ¬OÁÙ¯àÄ~Äò©êµÛ? ¦]¬°¨S¸I¹L³o¼Ëªº±¡ªp¡A½Ð¥ý¤F¸Ñ¤@¤U ¥ýÁÂÁ½ç±Ð¡A¤j®a¶g¥½´r§Ö |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/12/8 ¤U¤È 03:22:06²Ä 66 ½g¦^À³
|
¤½¶}¸ê°TÆ[´ú¯¸«¤j°T®§¤½§i (6497)¨È·à±d-KY-¤½§i¥»¤½¥q106¦~²Ä¤@¦¸ªÑªFÁ{®É·|«n¨Mij¨Æ¶µ 1.ªÑªFÁ{®É·|¤é´Á:106/12/08 2.«n¨Mij¨Æ¶µ: ¤@¡B°Q½×¨Æ¶µ: (1)³q¹L¥»¤½¥qÀÀ²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ®ü¥~¦s°U¾ÌÃҩοì²z°ê¤º²{ª÷¼W¸êµo¦æ´¶³qªÑ®×¡C (2)³q¹L¥»¤½¥qÀÀ¿ì²z²{ª÷¼W¸ê¨p¶Ò´¶³qªÑ®×¡C 3.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2017/12/8 ¤U¤È 02:34:41²Ä 65 ½g¦^À³
|
¥H¤U¤À¨É¶È¨Ñ°Ñ¦Ò ¦pªG¸³¨Æ·|¨M©w±Ä¥Î¨p¶Ò¡A¤@¨Ó¥i¥H§Ö³tÀò±o¸êª÷¶i¦æ§Þ³N´£¤É¡A±j¤Æ°ê»ÚÄvª§¤O¡A´£¤É¾ãÅé¬ãµo¯à¶q¡A§ïµ½°]°Èµ²ºcµ¥¦hºØ®Ä¯à¤S¤£·|ÅýÄw½X¹s¶Ã¡]¨p¶ÒªÑ²¼¤T¦~¤º¤£±oÂàÅý¡^ Ó¤H»{¬°±Ä¥Î¨p¶Ò¤è¦¡¬O¥¿±ªº¡A¥t¥~µo¦æ®ü¥~«H¦«¾ÌÃÒ ¤]¥¿±¥i¦æªº¶Ò¸ê |
|
|
·|û¡GMBE10145047 µoªí®É¶¡:2017/12/8 ¤U¤È 02:12:14²Ä 64 ½g¦^À³
|
¬°ÁקK»~¾É,«e¤å¥½¥y¯S¦¹§ó¥¿: ¨Ã«D¤jªÑªF¬O¤j©@,§ë¸ê¤H´N¤@©w±o¶R±b (ªÑ»ù»P¤½¥q»ùÈ,§ë¸ê¤H¤´¶·¦h¤è±µû¦ô) |
|
|
·|û¡GMBE10145047 µoªí®É¶¡:2017/12/8 ¤U¤È 01:37:34²Ä 63 ½g¦^À³
|
8/11¦b¦¹ª©¶K¤å´N¦³¦¹¾á¤ß ¥h¦~ªìF*AS¬O²Ä¤@®aºM¾P¦b¥xµo¦æªº¥~°Ó,¥D¦]¬O: §C¦¨¥æ¶q,ªÑ»ùªí²{¤£¨Î(EPS6.0~7.5¤¸,ªÑ»ù¥Ñ120±¾µP½w¨B½L¶^¦Ü8X) ³¡¤À¤jªÑªF¬°ºûÅ@¸gÀç»ùÈ,¬G¥Ñ³Ð¿ì¤H´£¥X¦¬Áʤwµo¦æªÑ¥÷ ¨È·à±d¥²¶·¦b±ÂÅv½Í§P¤ÎÁ{§É¸ÕÅ禳¶i®i ©Î¬O¦³·sªº¤j©@¤JªÑ,ªÑ»ù¤~·|¤ÏÀ³ (¥Ø«e´XÓ¤jªÑªF³£¬O¤j©@,¥i±¤¥xÆW§ë¸ê¤H¤£¶R±b) |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/12/8 ¤U¤È 12:23:34²Ä 62 ½g¦^À³
|
¥un¤½¥q¦³¶i«×,¹ê»Ú¿n·¥¦bÁ{§É¸ÕÅç¶i«×§V¤O, §ë¸ê¤H´N¥¼¨Ó«e´ºªº¹w´Á¶RÓ¥¼¨Ó¼ç¤O,ªÑ»ù·|¨ìþ½Ö¤]»¡¤£·Ç~~©È´N©È³oºØÄê»ù®æ, ¤½¥q´N±q¥xÆW¤U¥«¨ì¹ï©¤(ªü³°¥Jªº¥Í§Þ·sÃĪѫܵ¹¤O...)©Î·s¥[©Y«·s¤W¥«´N¦n....©Ò¥HªÑªF·|«á»°§ÖµoÓADRÄw¸ê, §â§ë¸ê»ùÈ©Ô¤W¥h§a!!! |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2017/12/5 ¤U¤È 02:29:13²Ä 61 ½g¦^À³
|
¦^ÂЫӰ¶¤j¡Aè襴¥h¤½¥q¸ß°Ý¡A¨S¿ù¤S¬O¤@¼Ëªº¸ê°T¦b³ø§i¤@¦¸¡A¬Ý¨Ó¥u¯àµ¥12/8ªÑªF·|¶}§¹ªºµ²ªG¤F¡A¸Ü»¡³ÌªñÁÙ¬O©Ó¾P°Ó³Í°ò¦b½æªÑ°Ú¡A¤jªÑªF¶°«O¨ì´Á«á¡A¥Ø«e¨S¦³¬Ý¨ìþ¤@Ó¤jªÑªF¦b°µ¤j¶qªº©ß°â¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2017/12/5 ¤U¤È 02:00:46²Ä 60 ½g¦^À³
|
À³¸Ó¤S¬O¤j¦P¤p²§ªº§ë¼v¤ù§a ÁÙ¬O´Á«ÝªÑªF·|«áÄw¸ê¤è¦¡©M±ÂÅv¤ñ¸û¹ê¦b |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2017/12/5 ¤U¤È 01:44:40²Ä 59 ½g¦^À³
|
©ú¤Ñ12/6¨È·à±d·|°Ñ¥[¨È¤Ó¥Í§Þ§ë¸ê½×¾Â¡A¤£ª¾¹D·|¤£·|·sªº®ø®§¤½¥¬©O? ³Ìªñ¥Í§ÞªÑ¯uªºÆZºGªº¡A¶^¶^¤£¥ð°Ú! |
|
|
·|û¡GMBE10145047 µoªí®É¶¡:2017/12/4 ¤W¤È 11:53:49²Ä 58 ½g¦^À³
|
YªÑªF·|³q¹L¼W¸ê¦Ó¸³¨Æ·|¨M©w¤£¨p¶Ò,®ü¥~¦s°U¾ÌÃÒ¬O¤w¤½§iªº¿ï¶µ¤§¤@ ¦]¬ü°ê¤£¬O¤½¥q»EµJªº¥«³õ,¤ñ¸û¥i¯à¥HGDRµo¦æ |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2017/12/4 ¤W¤È 10:52:57²Ä 57 ½g¦^À³
|
©t¨àÃĤj±z¦n¡A¥Ø«e¥Í§ÞªÑªº±¡ªp´N¬O¦p±z©Ò»¡ªº³o¼Ë¡A§Q¦h¤£·|º¦¡A¤j½L¤U¶^ÁÙ·|¸òµÛ¤@°_¶^¡A¤§«eASLAN003³q¹L·s¥[©Y½Ã¥Í¬ì¾Ç§½¤§«æ©Ê°©Åè©Ê¥Õ¦å¯f(AML)¤G´ÁÁ{§É¸ÕÅç¤HÅéÁ{§É¸ÕÅç¼f¬d¡A§Q¦h®ø®§¤]¤£·|º¦¡A¤W§«ô¥|¬ðµMº¦¤@¤U¡AÅý§Ú¥H¬°¨È·à±d²×©ón¤Ï¼u¤F¡Aµ²ªG¥u¬O¾èªá¤@²{¡A¥Ø«e¬Ý¨Ó¥u¯àµ¥«Ý±ÂÅvpµe½T»{¤§«á¡A¦³¹ê»Úª÷ÃB¤J±b¡AªÑ»ù¤~·|¶}©l¤Ï¼u§a¡A¦Ü©ó±z»¡ªºµo¦æADR¥i¥H«Øij¤½¥q¬Ý¬Ý! |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/12/4 ¤W¤È 10:16:50²Ä 56 ½g¦^À³
|
¥xÆW§ë¸ê¤H¹ï©ó¥Í§Þ·sÃĪº¬Ýªk, §Ú¬Û«H¦³¤G~~¤@¬°¤£¬Û«H®³¨ìÃÄÃÒ«á·|¦³¦h¤jªº°Ó¾÷(¦]¥xÆW¤H¤£·R²`¨sI«áªº¹D²z),¤G¬°¥xÆWÂåÀø¤Ó¦n¤Ó«K©y,¤j®a¤£»{¬°¤Ö¤F§A³oÃÄ·|¦º¤H;¦A¥[¤W«e°}¤l°òX¤Î¯EXªº¸Ñª¼¥¢±Ñ,¥xÆW§ë¸ê¤H¤£¬Û«H·sÃĥͧަ³¦ó«e´º? ©Ò¥H¬Ý¨Ó·à¤lªº¸êª÷»Ý¨DÁÙ¬O¥þ³¡µoADR¸û¨Î, Åý§ë¸ê»ùȦb°ê¥~³Q¬Ý¨£®É~~~Åý¥xÆW¤H¦A¨Ó°l°ª(·íµM¤£¥]§tªO¤Wªº¦U¦ì°ª¤âÌ~~~),³o¼Ë¤Wº¦¤O¹D§ó±j~~~ ¥H¤Wµoµo¨cÄÌ,¤j®a§O¤¶·N~~~ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/11/30 ¤U¤È 01:43:11²Ä 55 ½g¦^À³
|
ì¨Ó¤µ¤Ñ¦bº¦³oÓ~~~~ money.udn.com/money/story/11074/2847034 |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2017/11/30 ¤W¤È 11:31:39²Ä 54 ½g¦^À³
|
¤µ¤Ñ¥X¥G·N®Æªº©~µM¦³¶R½L ì¥H¬°©ú¤Ñ¤jªÑªF¥i¸ÑÂê½æªÑ¡A¤µ¤Ñ½æÀ£·|«Ü« ¦A¨Ó´N¬OnÆ[¹î¤U¶gªº±¡ªp¤F |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2017/11/30 ¤W¤È 09:26:12²Ä 53 ½g¦^À³
|
·j´M¨È·à±d¡A®É¶¡³]©w24¤p®É¤º ¦³¬ÛÃöÁ{§É»P±ÂÅv³ø¾É |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2017/11/30 ¤W¤È 12:10:28²Ä 52 ½g¦^À³
|
¨p¶Ò¥²»ÝÂêªÑ¤T¦~¡A¤S¯à¶Ò¨ì¸êª÷¶i¦æ¬ãµo¨ÖÁÊ¡A§ïµ½°]°Èª¬ªp¡A¤]¤£·|ÅýÄw½X¤Ó¶Ã¡A¤@Á|¼Æ±o¡C¥t¥~¤l¤½¥q¼W¸ê ¬O»P¥À¤½¥q¶¡ªº°]°È½Õ«×¡A¤£·|¼vÅTªÑªFÅv§Q¡C ¥H¤W¬OÓ¤H¬Ýªk¡A¥i¯à¬O°¾¨£¡A¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2017/11/29 ¤U¤È 11:21:23²Ä 51 ½g¦^À³
|
¤µ¤Ñªk»¡·|ªº¤º®eÁÙºâÆZ¥¿± ¦³»¡©ú¼W¸êªº¥Øªº¡A¸³¨Æªø¤]»¡·|¥Î¹ïªÑªF¦³§Qªº¤è¦¡¶Ò¸ê ¤£¹L±ÂÅv®×³Ì§Ö¥i¯ànµ¥©ú¦~ªì¤F ¬Ý¤½¥q½T¹ê¬O¦³¦b³W¹º¥¼¨Ó¸ô«ç»ò¨« ¤£¾Þ§ËªÑ»ù¡A»{¯u¦b¬ãµo¤W³o¤ßºA¬O¹ïªº |
|
|
·|û¡GMBE10145047 µoªí®É¶¡:2017/11/29 ¤U¤È 11:11:44²Ä 50 ½g¦^À³
|
©ú¤Ñ¤WÂdº¡¥b¦~,ªÑ»ù«o¶^¨ì©Ó¾P»ù¥´¹ï§é,§ë¸ê¤H¥²µM¬O¤£º¡·N ¦ý¥Ø«e¦@¦³¤¶µÁ{§É¸ÕÅ祿¶i¦æ©Îè±Ò°Ê,Ó¤H»{¬°ªÑ»ù¤]¨Ã¥¼¤ÏÀ³¥X¤½¥q¹ê»Úªº»ùÈ ¦Ó«ùÄòªº§C¶q,½L¶^,³o¦b¤½¥qªº¹w´Á¤§¥~,¬G¦A¼W¸ê¥H¨p¶Òªº¥i¯à©Ê¸û°ª ¦b·sªº±ÂÅv®×¤ÎÁ{§É¸ÕÅç¼Æ¾Ú¤½¥¬«e,¤£¥²´Á«ÝªÑ»ù·|¦³¤°»ò¹³¼Ëªº¨«¶Õ ¤½¥q¤]ªí¥Ü¤£·|¥h°µ¨ÇÅýªÑ»ù¤W¥hªº±¹¬I,³o¬OȱoªÖ©wªº |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2017/11/29 ¤W¤È 08:15:57²Ä 49 ½g¦^À³
|
¦pªG¯à¿ï¾Ü¹ïªÑªF¦³§Qªº¶Ò¸ê¤è¦¡·íµM¬O³Ì¦nªº ³Ì¦n©_ªº¬O¤½¥q²³øºÙ²{¦³¸êª÷¥i¥Î¦Ü2019 ¨º³o¦¸¶Ò¸êªº¥Øªº?(¥i±¤¨S·à¤Í¯à¥hªÑªF·|¸ß°Ý) §Æ±æ¬O¦³¹ê½è¥Î³~ªº¡A¨Ò¦p¨ÖÁÊ¡B¤Þ¶i¤jÃļt¸êª÷¡BÁ{§É©¹«e±À¶i...µ¥ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/11/28 ¤U¤È 04:12:12²Ä 48 ½g¦^À³
|
¸¤H¤j¤j,±z¦n... À³¸Ó¬O¤£¯à¥h°Ñ¥[¤F...n¤W¯Z°Ú~~§Æ±æ¥¼¨Óªº¼W¸ê¬O¥ÎADR¤ñ¸û¯à¥´¶}°ê»Ú¥«³õ©Î¬OÅýMERCK¤Î²H°¨¿ü»{ªÑ,Åý¨âӼϯøÕÅ窺»ùȯà¹üÅãªü~~~ |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2017/11/28 ¤U¤È 03:58:49²Ä 47 ½g¦^À³
|
¤£ª¾¹D©t¨àÃĤj¤j·|¥h©ú¤Ñªºªk»¡·|¶Ü? «e´X¤Ñ¥´¹q¸Ü¥h¨È·à±dªº§ë¸ê¤H±M½u¡A¥LÌ«Øij¦pªG¹ïªÑ»ù¦³ºÃ¼{ªº§ë¸êªÌ¡A¥i¥H¥h°Ñ¥[ªk»¡·|´£°Ý¡A¸³¨Æªø·|µ¹¤©¦^À³ªº¡A¥LÌû¤u»{ªÑ»ù¤]¬O©Ó¾P»ù68¡A¥L̤]¬O«Ü¾á¤ß¡AªÑ»ù¤@ª½ª½ª½¸¨¡A¤£¹LªÑ»ù³oºØ¨Æ¡A¤½¥q¤]¨S¿ìªk¤z¯A¡A²¦³º¬O¦Û¥Ñ¥«³õ¡AªÑ»ù¬O¥Ñ¥«³õ¨M©wªº¡A²{¦b´N¬O§ë¸ê¤H¹ï¨È·à±d¨S¦³«H¤ß¡A©Ò¥H¨S¬Æ»ò¤Hn¶i³õ¡A¥u³Ñ¤U¾á¤ß12/1¤jªÑªF·|©ß°â«ùªÑªº§ë¸ê¤H¡A¨C¤Ñ¦b¨ºÃä¥áªÑ²¼¡A²{¦b¥u¯àµ¥µ¥¬Ý¡A¬ÝªÑªF·|ªÑªF·|¦³¤°»ò¼Ëªº¤ÏÀ³¡AÁÙ¦³¤½¥q¹ïªÑ»ù·|°µ«ç»ò¼Ëªº»¡©ú¤Î©ú¦~ªºµo®i¤F¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/11/28 ¤U¤È 02:54:54²Ä 46 ½g¦^À³
|
¤½¶}¸ê°TÆ[´ú¯¸«¤j°T®§¤½§i (6497)¨È·à±d-KY-¥»¤½¥q¨üÁÜ°Ñ¥[³Í°òÃÒ¨é¥D¿ì¤§R&D Day®y½Í·| ¨Æ¹êµo¥Í¤é¡G106/11/29 ·|ij¸ê®Æ³sµ²¦p¤U(»P¥ý«e¸ê®Æ´X¥G¬Û¦P): mops.twse.com.tw/mops/web/t100sb07_1 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2017/11/20 ¤U¤È 12:03:35²Ä 45 ½g¦^À³
|
¸¤H¤j ª©¥D´£¨ÑªºÁpµ²´N¥i¬Ý¨ì^¤åª©Â²³ø¡A¼¯®Ú¥v©Z§Q¦b·s¥[©YÁ|¿ìªºªk»¡·|¤£·|¦³¤¤¤åª©¡A¦b¤½¶}¸ê°TÆ[´ú¯¸¬Ý¨ì¤¤¤åª©¨ä¹ê¬O^¤åª©¡A·s¥[©Y¬O°ê»Ú¤Æ«Ü´ú©³ªº°ê®a¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2017/11/20 ¤W¤È 10:07:36²Ä 44 ½g¦^À³
|
Future Milestones 2017-2018 ¤]´£¨ÑAslan001 »PAslan003 Á{§É¼Æ¾Ú¤½§i¡A001¤½§i¤TӼƾڡA003¤½§i¤@ӼƾڡA2019¦~Áx¹DÀù±N¦b¥Dn¥«³õ´£¥XÃÄÃÒ®Öã¥Ó½Ð |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2017/11/20 ¤W¤È 10:00:40²Ä 43 ½g¦^À³
|
³Ì«á¤@¶ Future Milestones 2017-2018 ´£¨ÑAslan001 »PAslan003 »P¦X§@¹Ù¦ñ±ÂÅv¥æ©ö |
|
|
·|û¡GMBE10145047 µoªí®É¶¡:2017/11/20 ¤W¤È 09:29:37²Ä 42 ½g¦^À³
|
¸¤H¤j, Âà¶Kª©¥D´£¨Ñªº³sµ²,¤º¦³^¤å²³øÀÉ mops.twse.com.tw/mops/web/t100sb07_1 ¤£¹L,¤º®e»P¤½¥q©xºô9/14ªk»¡¤¤¤åÀÉ,¨ÃµL¤Ó¤j®t²§ |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2017/11/20 ¤W¤È 09:15:31²Ä 41 ½g¦^À³
|
¤£ª¾¹D¥xÁÞ¤j¡A¥i§_§iª¾þÃ䦳¤W§«ôªk»¡·|ªºÂ²³øÀÉ¥i¥H°Ñ¦Ò©O? |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2017/11/20 ¤W¤È 12:22:45²Ä 40 ½g¦^À³
|
¤W«h¤À¨É¸É¥R ¨Ì¾Úªk»¡·|²³ø¡AAslan001GÀù¤@½u¤G/¤T´ÁÁ{§É¸ÕÅç2018¦~·|¤½§i¤G´ÁORR¼Æ¾Ú¡]«e40¦ì¨ü¸Õ¡^ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2017/11/20 ¤W¤È 12:02:07²Ä 39 ½g¦^À³
|
¨È·à±d¨üÁÜ°Ñ¥[¼¯®Ú¥v©Z§Q¦b·s¥[©Y¤åµØªF¤è°s©±¥l¶}ªºªk»¡·|²³øÀɳ̫á¤@¶¬O«ÂIºëµØ¡A Aslan001 ¤µ¦~·|¦³°Ï°ì©Ê¦X§@¹Ù¦ñ¨üÅv¥æ©ö¡A ©ú¦~¤]·|¦³¡AÀ³¸Ó¬O¤é¥»¡A¼Ú·ù¡A¤¤°ê¤§±ÂÅv¡AAslan003«æ©Ê°©Åè©Ê¥Õ¦å¯f©ú¦~·|¤½§i¤G´Á¼Æ¾Ú»P¦X§@¹Ù¦ñ½Í¨üÅv®×¡A¤]´N¬O»¡¦b2018¦~«e·|¦³¥|Ó°Ï°ì©Ê¨üÅv¥æ©ö¡C ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò¡A¤Å§@¬°§ë¸ê¤§¨Ì¾Ú¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/11/19 ¤U¤È 04:58:40²Ä 38 ½g¦^À³
|
¨üÁÜ©óMorgan StanleyÁ|¿ì¤§16th Annual Asia Pacific Summit¤¤¶i¦æ¤½¥q³ø§i¡A·|¤¤´N¥»¤½¥q¤w¤½¶}µo§G¤§Àç¹B¤Î°]°È·~°Èª¬ªp§@»¡©ú mops.twse.com.tw/mops/web/t100sb07_1 |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/11/10 ¤W¤È 10:32:58²Ä 37 ½g¦^À³
|
ÁöµM³o¨ÅÀùªº¸ÕÅç¶È¦b¤G´Á,¦ý¥Ñ´¦ÅSªº¼Æ¾Ú¨Ó¬Ý,³£¥i¥H±ÀºV¦b¥¼¨Ó¦bÁxºÞÀù¤ÎGÀù¼Ï¯Ã¸ÕÅç¥H§í¨îErbB family (EGFR, HER2 and HER4)¬°¥Dn³~®|ªº¥¼¨Óµ²·í¦¨«ü¤Þ~~~¤p§Ìı±o³o¨Çµ²ªG±N«D±`¨ã¦³«ü¼Ð©Ê·N¸q.... ¤G´Á¨ÅÀùµ²ªG: Results From Dec 2014 to Aug 2016, 24 patients were randomized to the VC arm (400mg BID) and 26 to the LC arm (1250mg QD) in 16 sites in 6 countries. Percentage of tumor size reduction was numerically higher in VC than LC (-31.00% vs. -19.37%, one-sided p = 0.132). ORR in the VC arm (40.9%) was similar to LC arm (45.5%), p = 1.000. Sensitivity analysis showed numerically superior ORR and statistically significant higher reduction of tumor size in VC compared to LC (60% vs. 45.5%, p = 0.508; mean, -34.6% vs.-19.4%, one-sided p = 0.075) All patients had at least 1 AE. Severe AE(s) were observed in 13 patients (54.2%) in the VC arm and 11(42.3%) in the LC arm. The most common AE was diarrhea (66.7%) in the VC arm and were diarrhea and palmar-plantar erythrodysaesthesia syndrome (both 50%) in the LC arm. Median intended exposure and percentage of intended dose were lower in the VC arm (115.5 days, 74.6%) indicating more frequent dose interruption, dose reduction and treatment discontinuation than the LC arm (135.0 days, 99.05%). ¥H¤W¨Ñ°Ñ¦Ò~~~¡Ä |
|
|
|